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1 INTRODUCTION 
 
1.1 G protein-coupled receptors (GPCRs) 
 
The G protein-coupled receptor superfamily is one of the largest protein families, accounting for 
about 3% of the human genome. This family of membrane proteins is constituted by more than 
800 genes and it is characterized by two fundamental elements, i.e. the presence of seven 
membrane-spanning helixes and the coupling to signaling proteins known as G proteins 
(Fredriksson et al., 2003). These receptors are also referred to as seven transmembrane helix 
(7TM) receptors, definition that is even more suitable than GPCRs, considering that not all 7TM 
receptors signal through G proteins (Pierce et al., 2002). The aforementioned receptors display 
several common features, i.e. an N-terminal extracellular domain, a C-terminal intracellular 
domain, three extracellular loops and three intracellular loops (Figure 1.1).  
 
Figure 1.1: Common molecular architecture of GPCRs consisting of seven transmembrane domains. GPCR 
activation triggers signalling mediated by their membrane-bound partners, the heterotrimeric G proteins, 
which regulate a broad range of biological processes. cAMP, cyclic AMP; PI3K, phosphoinositide 3-kinase; 
PKA and PKC, protein kinase A and C; PLCβ, phospholipase Cβ; Rho, RAS homology; RGS, regulator of G 
protein signalling. Modified after Lappano and Maggiolini (2011). 
 
GPCRs recognize a variety of diverse extracellular stimuli (e.g., photons, ions, biogenic amines, 
peptides, lipids and proteins, among others) and transduce their signals into the intracellular 
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environment via conformational rearrangements that cause the exposition of binding sites for 
cytosolic interactants, which then propagate the signaling within the cell (Pierce et al., 2002; 
Lefkowitz, 2004). Despite sharing a common structure, these receptors are characterized by a 
relatively low sequence identity (less than 20%) (Fredriksson et al., 2003). Vertebrate GPCRs are 
commonly divided into five main families, based on their sequence and structure similarities. 
Family A, that is the rhodopsin-like receptor group, comprises the largest number of receptors 
(701, of which 241 are non-olfactory), whose ligands are peptides, proteins, lipid-like substances, 
fatty acid derivatives, small organic compounds, photons and nucleotides. Family B is constituted 
by the human secretin-like receptors and includes 15 members. They bind rather large peptides 
that share high amino acid identity and usually act in a paracrine manner. Family C is known as the 
glutamate receptor family, which comprises 15 members, including metabotropic glutamate, 
GABAB, and calcium-sensing receptors. A fourth family is represented by the adhesion receptors, 
and it is composed of 24 members, which present one or several functional domains with 
adhesion-like motifs in the N terminus. Finally, there is a fifth family, the frizzled/Taste2 family, 
which comprises 24 receptors. Among them, the TAS2 receptors mediate the human bitter taste, 
while the frizzled receptors bind secreted Wnt proteins, as well as other ligands, and play a critical 
role in the regulation of cell polarity (Fredriksson et al., 2003; Lagerström and Schiöth, 2008). 
 
1.1.2 GPCRs activation 
 
Regardless of the structural diversity of the ligands and ligand binding sites within the family of 
GPCRs, these receptors act through a similar molecular mechanism: the binding of extracellular 
ligands to GPCRs causes a conformational change in the receptor that promotes the coupling with 
distinct classes of guanine nucleotide-binding proteins (G proteins). These G proteins are 
heterotrimeric proteins consisting of an α-subunit bound to a βγ complex and are anchored to the 
cytoplasmic surface of the plasma membrane. There are several types of G proteins, classified in 
four broad classes: Gs, Gi/o, Gq/11 and G12/13 (Figure 1.1), with coupling preference being determined 
by the individual receptor species (Simon et al., 1991; Milligan and Kostenis, 2006). 
Interaction of the ligand-activated receptor with the G protein stimulates the exchange of GTP for 
GDP in the α-subunit, resulting in the dissociation of the G protein from the receptor and the 
dissociation of the G protein α-subunit from the βγ complex. The G-protein subunits, α-GTP and 
free βγ, are then able to interact with distinct effector enzymes and ion channels, stimulating 
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different physiological responses. Since all α-subunits possess intrinsic GTPase activity, α-GTP is 
ultimately hydrolyzed to α-GDP, which is able to bind free βγ complexes with high affinity. This 
reaction returns the system to the original resting state (Wess, 1998). Despite this being the 
common model of G protein activation, it was discovered that G protein subunits of the Gi/o 
subtype undergo a molecular rearrangement rather than dissociation during activation 
(Bünemann et al., 2003; Frank et al., 2005). Regarding G proteins of the Gs family, it was instead 
confirmed that they actually dissociate from the βγ complex (Janetopoulos et al., 2001).  
Many mechanisms are known to fine-tune and regulate GPCR signaling. One of the most 
intensively studied is the “desensitization”, which is achieved through receptor phosphorylation 
mediated either via second messenger kinases (protein kinase A (PKA) or protein kinase C (PKC)), 
or via G protein-coupled receptor kinases (GRKs). Phosphorylation carried out by PKA or PKC is 
known to cause a direct uncoupling of the receptor from the G protein, while GRK-mediated 
regulation involves the contribution of a small family of cytosolic proteins known as β-arrestins 
(Pierce et al., 2002). In this two-step process, agonist-occupied GPCRs become substrates for GRK-
mediated phosphorylation and, in turn, the phosphorylated receptors recruit the cytosolic 
adaptors of the β-arrestin type. Further G-protein activation is blocked by β-arrestin-binding, 
which sterically impedes access to the receptor binding domains, causing desensitization of 7TMR-
G protein signaling (Benovic et al., 1987). Additionally, β-arrestins can act as scaffold for enzymes 
such as phosphodiesterase or kinases, which degrade second messengers generated by G protein-
coupling (Perry et al., 2002; Nelson et al., 2007), and they are also involved in receptor 
internalization via clathrin-coated vesicles (Moore et al., 2007). Furthermore, it was discovered 
that in many cases β-arrestins function as receptor-activated scaffolds to coordinate upstream and 
downstream components of particular signal transduction pathways, indicating that these proteins 
take part in the agonist-induced signaling events, and not only in the switch-off of the signaling 
cascade (Shenoy and Lefkowitz, 2011). 
 
1.2 Influence of sodium on GPCRs 
 
In the recent past, X-ray crystallography on GPCRs allowed the resolution of an increasing number 
of receptor structures, permitting an accurate mapping of amino acidic residue orientation and of 
the location of ligand binding sites. Lately, the improvement of this technique led to high 
resolution structures in which also the position of water molecules and ions could be identified. In 
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particular, the presence of a sodium ion bound to an allosteric site in the transmembrane region 
was recognized at several class A GPCRs in their inactive state (Katritch et al., 2014), i.e. the 
adenosine A2A receptor, the protease-activated receptor 1, the adrenergic β1 receptor and the 
delta opioid receptor, and was shown to maintain the receptor in a quiescent state (Wu et al., 
2012; Zhang et al., 2012; Fenalti et al., 2014; Miller-Gallacher et al., 2014). The fact that sodium 
ions have a negative influence on the activation of GPCRs was not unexpected. Indeed, the first 
report describing sodium ions as negative allosteric modulators dates back to 1973, when Pert and 
Snyder (1973) divulged that 100 mM NaCl, i.e. a relevant physiologic concentration, increased 
antagonist affinity and decreased agonist binding at opioid receptors. Numerous following reports 
described the effects of sodium ions, mainly in the form of NaCl, as modulators of GPCRs signaling 
and binding. The results of these studies are not conclusive and a uniform effect of Na+ on GPCRs 
has not been identified so far. Indeed, investigations on the effect of this cation on ligands showed 
that in most of the cases the affinity of agonists is reduced upon an increase in Na+ in the buffer 
(Pert and Snyder, 1973; U'Prichard and Snyder, 1978; Rosenberger et al., 1980; Neve, 1991; 
Malmberg and Mohell, 1995). When NaCl was tested against antagonist’s affinities, it was rather 
noted that their affinity was either increased (Pert and Snyder, 1973; Malmberg and Mohell, 
1995), left unaltered (U'Prichard and Snyder, 1978), or diminished (Rosenberger et al., 1980). 
Additionally, NaCl was shown to have differential effects at the same receptor (α2AR) when several 
agonists were tested, and was found to either increase or decrease their affinity at 40 mM NaCl 
compared to 0 mM NaCl (Pihlavisto et al., 1998), further demonstrating that generalizations on the 
entity and orientation of Na+ influence on ligand affinity are not feasible.  
 
1.3 Classification of GPCRs ligands 
 
The two biological properties of a GPCR ligand that can be quantified and are used to 
pharmacologically characterize a drug, are affinity and efficacy. The first one is a measure of the 
avidity of the ligand for the binding site of the receptor and it can simply be measured and 
quantified by the calculation of the parameter KA, i.e. the dissociation constant of ligand binding at 
the receptor protein (Shonberg et al., 2014). Efficacy is a parameter that was proved to be more 
difficult to quantify, for instance, in case of cellular signal amplification and in particular after 
emerging evidences that a receptor can couple to multiple signaling pathways and may have a 
preference for a specific downstream effect, a phenomenon known as biased signaling (see 1.4) 
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(Urban et al., 2007; Kenakin, 2011). Classically, according to the two-state model of receptor 
activation (Leff, 1995), an agonist is considered the molecule that shifts the equilibrium of the 
receptors, which exist in active and inactive forms, towards the active state, stimulating the 
corresponding effect; an antagonist, instead, is thought to bind the active and inactive state with 
the same affinity, having a “silent” effect (Kenakin, 2002). With the observation that receptors can 
display constitutive activity, i.e. they can stimulate downstream signaling even in the absence of 
an agonist (Samama et al., 1993; Milligan, 2003), many antagonists were reclassified as inverse 
agonists, i.e. drugs that bind preferentially to the inactive state, inhibiting constitutive receptor 
activity. Another class of ligands is that of partial agonists. In fact, not all agonists display a fully 
agonistic efficacy, e.g. that reported for the endogenous ligand, but they may display submaximal 
efficacies even at full receptor occupancy. Conversely, there is also a recently identified class of 
ligands, the so-called superagonists, which are ligands endowed with a greater efficacy than the 
endogenous agonist (Schrage et al., 2013; Schrage et al., 2015). Superagonists have been reported 
for several GPCRs, e.g. muscarinic M2 and M4 receptors, ghrelin receptor and somatostatin sst4 
receptors among others (Engström et al., 2005; Holst et al., 2005; Bennett et al., 2009; Schrage et 
al., 2013).  
 
1.3.1 Protean agonism 
 
A particularly fascinating, albeit seldom described, category of GPCR ligands are protean agonists, 
i.e. compounds which display agonism in quiescent receptor systems without any spontaneous 
receptor activity and inverse agonism in constitutively active systems (Kenakin, 1995a). In other 
words, protean agonists change the direction of their effect according to the degree of 
spontaneous activity of the GPCR to which the compound binds. One explanation for this 
intriguing phenomenon is thought to reside in the efficacy of the ligand bound-receptor complex. 
Theoretically, if a ligand-receptor complex has an intrinsic efficacy that is lower than that of the 
spontaneously active receptor, but still higher than the efficacy of the quiescent receptor, this will 
result in (i) negative agonism in a system mainly composed by constitutively active receptors, since 
receptor activation would be diminished, or (ii) partial agonism, if most of the receptors are in the 
quiescent state (Kenakin, 1995a, 1997) (Fig. 1.2).  
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Figure 1.2: Proposed mechanism of action of protean agonists. The ligand produces a pseudo-active state 
(Ra, triangle) that promotes a response with a lower efficacy than the naturally active state (Ra, circle). In a 
quiescent system, the increase in Ra triangle produces an increased agonist response. However, in a 
spontaneously active system, the agonist converts the constitutively active state receptor to a less 
efficacious species, reversing constitutive agonism. Source: Kenakin (1997).  
Up to now, although virtually conceivable for all GPCRs, protean agonists have only been identified 
for a small number of receptors, for instance cannabinoid receptor 2 (CB2) (Yao et al., 2006; 
Mancini et al., 2009; Xu et al., 2010; Bolognini et al., 2012), histamine receptor 3 (H3) (Gbahou et 
al., 2003a), alpha-2A adrenergic receptor (α2AAR) (Jansson et al., 1998; Pauwels et al., 2002), 
serotonin receptor 1B (5-HT1B) (Newman-Tancredi et al., 2003), bradykinin receptor 2 (B2) (Fathy 
et al., 1999; Marie et al., 1999) and beta-2 adrenergic receptor (β2AR) (Chidiac et al., 1994; Chidiac 
et al., 1996). Nevertheless, protean agonists are highly valuable tools as they might be most useful 
for the identification of ligand-specific active states of GPCRs: these compounds select a particular 
receptor conformation that is different from both the spontaneously formed and the full-agonist 
induced conformation (Kenakin, 2011). Furthermore, protean agonists may represent a promising 
new compound class in targeted drug therapy for those cases in which receptor mutations cause 
constitutive activity. Under these conditions, protean agonists can re-establish the original tone of 
receptor activation (Jansson et al., 1998; Mancini et al., 2009). Moreover, the identification of 
protean agonists is of significant importance, because they may be mistaken for inverse or partial 
agonists in in vitro assays (in which constitutive receptor activity might be an unwanted 
phenomenon in commonly applied receptor overexpressing systems) (Chidiac et al., 1994), but act 
as agonists in vivo (Yao et al., 2006; Mancini et al., 2009; Xu et al., 2010). The rather few examples 
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of GPCR protean agonists are, at least in part, due to the lack of experimental systems with a 
reliable and reproducible amount of spontaneous GPCR activity. Moreover, specific design 
strategies to generate protean ligands are missing. 
1.4 Orthosteric and allosteric binding sites 
 
GPCRs possess an orthosteric site, which is the binding site of the endogenous agonist. Beyond the 
endogenous ligands, also classic competitive antagonists, inverse agonists and exogenous agonists 
can target the orthosteric site. Historically, GPCR-based drug discovery had focused on the 
development of more selective and/or potent ligands that act at the orthosteric site of the 
receptor of interest. This approach has the advantage of endowing selectivity and specificity in 
activity to the investigated drugs. On the other hand, the major drawback was shown to be a lack 
in subtype selectivity, considering that some GPCR families display high sequence conservation 
within the orthosteric binding domain across receptor subtypes (May and Christopoulos, 2003; 
Wess et al., 2007). A new possibility to develop subtype-selective ligands emerged with the 
discovery of the presence of allosteric sites on several GPCRs, e.g. muscarinic, adenosine, 
adrenergic, dopamine and serotonin receptors (Lüllmann et al., 1969; Stockton et al., 1983; Conn 
et al., 2009). An allosteric site is defined as a modulatory binding site, topographically distinct from 
the orthosteric site; allosteric ligands, also known as allosteric modulators, are able to fine-tune 
receptor activity through conformational changes in the receptor protein. These modifications are 
transmitted from the allosteric site to the orthosteric site and/or directly to effector coupling sites, 
while still allowing, in many instances, the concomitant binding of orthosteric ligands. The 
simultaneous binding of the receptor by an orthosteric and an allosteric ligand is referred to as 
“ternary complex formation” (Christopoulos, 2002).  
Since the discovery of the phenomenon of allosterism, several models have been developed to 
describe this mechanism; the first was proposed by Monod, Wyman and Changeux (MWC model), 
who suggested that a protein exists in a spontaneous equilibrium between active and inactive 
states in the absence of ligand, and that the binding of either an orthosteric ligand or an allosteric 
modulator to the respective binding sites would stabilize one state at the expense of another; the 
apparent effect that the presence of one ligand has on the other ligand was referred to as the 
allosteric interaction (Monod et al., 1965).  
Afterwards, the “allosteric ternary complex model” (ATCM) was developed (Stockton et al., 1983; 
Ehlert, 1988), which assumes cross-interactions between topographically distinct sites. It describes 
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the simplest allosteric effect, i.e. a reciprocal modulation of ligand affinity, in terms of the 
respective dissociation constants (KA, KB) that an orthosteric ligand, A, and an allosteric modulator, 
B, have for their binding sites on the unoccupied receptor. This model introduces a new 
parameter, termed the “cooperativity factor”, α, which quantifies the magnitude by which the 
affinity of one ligand is changed by the other ligand (and vice versa) when both are bound to the 
receptor to form the ternary complex, and the extent to which the dissociation constant of each 
ligand is modified in the presence of the other. Values of α greater than 1 indicate an allosteric 
reduction of affinity for the receptor (negative cooperativity); values of α between 0 and 1 denote 
an allosteric enhancement in affinity (positive cooperativity); an α value equal to 1 represents no 
net effect on binding affinity at equilibrium (neutral cooperativity). The limitation of this model is 
that it does not consider the isomerization of a GPCR between the active and inactive state (Hall, 
2000). 
The ATCM model was therefore extended in the “allosteric two-state model” (ATSM) (Hall, 2000), 
which explicitly incorporates the isomerization of a receptor between active (R*) and inactive (R) 
states, and introduces additional coupling constants to describe the selective stabilization of these 
states by orthosteric and allosteric ligands. 
Since orthosteric and allosteric ligands display reciprocity of effect if present together, the 
phenomenon of allosterism exhibits several peculiar properties; first, the effect is saturable, which 
means that there is a limit in the allosteric effect at high concentration of modulator, so that the 
efficacy of the highest concentration of modulator on orthosteric ligand potency approaches a 
limit above which no further allosteric modulation is observed (Hall, 2000; Christopoulos, 2002; 
Chan et al., 2008). A second characteristic is the “probe dependence”: the extent and direction of 
an allosteric interaction can vary with the nature of the orthosteric ligand used as a probe of 
receptor function, because different orthosteric ligands induce different receptor conformations 
that alter the structure of the allosteric binding site (Watson et al., 2005; Leach et al., 2010). And 
third, allosteric modulators can exert differential effects on affinity and efficacy of orthosteric 
ligands (Price et al., 2005); they can act on these two parameters in opposite ways, for example 
showing a positive cooperativity at the level of ligand binding and a negative cooperativity at the 
level of orthosteric ligand function.  
Another important advantage of allosterism is the possibility of obtaining selective activation of 
specific cellular signaling pathways at the expense of others. This phenomenon was first proposed 
on theoretical grounds based on experimental findings that were inconsistent with the concept of 
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a single receptor active state, and was referred to as “stimulus trafficking” (Kenakin, 1995b). This 
theory, now known as “biased agonism” or “functional selectivity” (Urban et al., 2007; Violin and 
Lefkowitz, 2007), was confirmed by many experimental data that show that different agonists do 
not uniformly activate all pathways in cells to which receptors are coupled (Kenakin, 2003; Urban 
et al., 2007). This selective receptor activation is a consequence of the existence of numerous 
receptor conformations capable of signaling (Kjelsberg et al., 1992); a modulator may then 
selectively bind to one of these conformers, thereby increasing the proportion of this conformer in 
the total protein population and producing the observed effect (“conformational selection”), or it 
can convert the protein into a conformation that it would not spontaneously adopt in its unligated 
state (“conformational induction”) (Teague, 2003). These different conformations may show 
altered position of amino acids in numerous locations, allowing or preventing the binding of the 
receptor to an effector protein (Kenakin, 2007). The importance of biased agonism resides in the 
fact that allosteric modulators could then be exploited not only to achieve receptor specificity, but 
also signaling selectivity. 
 
1.5 Muscarinic acetylcholine receptors 
 
Acetylcholine is a neurotransmitter present in both the peripheral nervous system (PNS) and 
central nervous system (CNS), that exerts its action through two different types of receptors: the 
nicotinic acetylcholine receptors (nAChRs, also known as "ionotropic" acetylcholine receptors), 
which are particularly responsive to nicotine, and the muscarinic acetylcholine receptors (mAChRs, 
also known as "metabotropic" acetylcholine receptors), which are particularly responsive to 
muscarine (Hulme et al., 1990). 
The mAChRs belong to the family A of GPCRs; there are five different subtypes that have been 
discovered through pharmacological and genetic studies, classed M1-M5, with different patterns of 
distribution and functions (Bonner et al., 1987; Bonner et al., 1988). All the mAChRs are expressed 
in many regions of the CNS (in both neurons and glial cells) and in various peripheral tissues. The 
M1, M4 and M5 receptors are predominantly expressed in the CNS, whereas the M2 and M3 
receptor subtypes are widely distributed in both CNS and peripheral tissues. It is also known that 
most tissues and cell types express at least two or more mAChR subtypes (Wess et al., 2007).  
A broad number of behavioral, cognitive, sensory, motor and autonomic processes are regulated 
by central mAChRs, and changes in the expression levels and activity of these receptors are 
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implicated in the pathophysiology of many CNS diseases, including Parkinson’s and Alzheimer’s 
disease, depression, schizophrenia and drug addiction. The functions of peripheral mAChRs 
include ACh-mediated decrease in heart rate (M2) and increase in smooth-muscle contractility and 
in glandular secretion (M3), actions mediated by mAChRs on effector tissues that are innervated by 
parasympathetic nerves. A broader overview of the processes mediated by the different subtypes 
of mAChRs is presented in Table 1.1.  
 
 
Table 1.1: Physiological processes mediated by muscarinic subtypes in CNS and PNS. Adapted from Wess 
(2004). 
 
The M1–M5 receptors can be subdivided into two major functional classes according to their G 
protein-coupling preference: the odd-numbered receptors preferentially couple to G proteins of 
the Gq/11 family, activating phospholipase C beta (PLC) and mobilizing calcium ions from 
intracellular stores (e.g. the endoplasmatic reticulum), whereas the even-numbered receptors 
preferentially activate Gi/o-type G proteins, inhibiting adenylyl cyclase and reducing the 
intracellular concentration of cAMP (Wess et al., 2007; Langmead et al., 2008). 
Even though each receptor subtype has a specific coupling preference, it was proven that all five 
mAChR subtypes couple promiscuously to multiple G proteins, usually in a cell background 
dependent manner. Moreover, they are linked to additional intracellular pathways, including 
activation of mitogen activated protein kinases, Rho GTPases, nitric oxide synthases, multiple 
phospholipases, and the modulation of a variety of potassium, calcium and chloride ion channels 
(Lanzafame et al., 2003).  
 
 
 
Gi/o-coupled receptors: Gq/11-coupled receptors: 
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1.5.1 M2 receptor 
 
The M2 muscarinic acetylcholine receptor (M2 receptor) is largely distributed in both CNS and 
peripheral tissues, and it is essential for the physiological control of cardiovascular function. It is 
indeed efficiently coupled to G proteins of the Gi/o class, which mediate the inhibition of adenylyl 
cyclase, resulting in a decrease of cAMP accumulation and attenuation of cAMP-dependent 
signaling (Ashkenazi et al., 1987). Following M2 activation, the released βγ subunits interact with a 
specific subtype of G protein-coupled inwardly-rectifying potassium channels (GIRKs) named IKACh, 
set in the heart. This ion channel, once activated, opens and becomes permeable to potassium 
ions, resulting in hyperpolarization of the cell (Reuveny et al., 1994). The M2 receptor represents 
the prevailing subtype of muscarinic receptor in the heart (Krejcí and Tucek, 2002); the principal 
effects of its stimulation are hyperpolarization and a slowed spontaneous depolarization, resulting 
in reduced sinus nodal rate in the sinoatrial node, a shortened action potential duration, a 
decreased contractile force in the atrium, a decreased conduction velocity in the atrioventricular 
node and finally a slight decrease in force of the ventricle (Dhein et al., 2001).  
The M2 receptor is considered a “model receptor” for the study of allosterism since allosteric 
regulation of GPCRs was first observed for this receptor (Doughty and Wylie, 1951; Della Bella et 
al., 1961; Lüllmann et al., 1969; Brown and Crout, 1970; Rathbun and Hamilton, 1970), and it has 
been one of the most extensively characterized allosteric model systems. It is known that the M2 
receptor presents at least two allosteric sites; the best characterized one is referred to as the 
“common” allosteric site, and is present in all five muscarinic receptors, but it displays different 
affinities for allosteric modulators depending on the receptor subtype. Generally, M2 is the 
receptor that has the highest affinity for many “common-site” modulators, such as gallamine (Ellis 
et al., 1993; Gnagey and Ellis, 1996), alkane-bis-ammonium type compounds (Buller et al., 2002) 
and alcuronium (Jakubík et al., 1995), while M5 is the one that has the lowest affinity for these 
compounds. The residues which are important for allosteric modulators selectivity and affinity 
were identified through site-directed mutagenesis studies, the use of receptor chimeras (Ellis et 
al., 1993; Gnagey and Ellis, 1996; Buller et al., 2002; Huang et al., 2005; Prilla et al., 2006), and 
from the recently published crystal structure of the active M2 bound to an allosteric modulator 
(Figure 1.3) (Kruse et al., 2013). The position of the “common” allosteric site was identified as 
being located at the opening of the orthosteric binding pocket, in the extracellular loop region of 
the receptor.  
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Figure 1.3: A) Overall structure of the active-state M2 receptor in complex with the orthosteric agonist 
iperoxo and the active-state stabilizing nanobody Nb9-8. B) Cross-section through the membrane plane of 
the region comprising allosteric and orthosteric binding sites. The allosteric ligand LY2119620 binds to the 
extracellular vestibule just above the orthosteric agonist. Modified after Kruse et al. (2013). 
 
A cluster of acidic amino acids, the EDGE sequence (residues 172-175), located in the third 
extracellular loop, was found to be critical for gallamine affinity, and it is also considered to play an 
important role in the interaction between the allosteric and orthosteric binding sites (Leppik et al., 
1994).  Three amino acids were identified as lining the core region of the allosteric site, Tyr177, 
Thr423 and Trp422, and they were shown to have a key role for the binding of allosteric agents 
(Buller et al., 2002; Voigtländer et al., 2003; Prilla et al., 2006). Analysis of the active crystal 
structure of M2 further supported these mutagenic studies, highlighting that Trp422 engages an 
aromatic stacking interaction with the allosteric modulator LY2119620, crystallized in complex 
with iperoxo to the receptor (Kruse et al., 2013).  
 
1.6 Dualsteric ligands and dynamic ligand binding 
 
In order to obtain molecules that are able to bind both the orthosteric and allosteric sites of the 
muscarinic receptors, and that, as a consequence, could provide subtype-specific binding, 
heterobivalent allosteric/orthosteric compounds were synthesized. The first work reporting the 
rational engineering of these new type of molecules, named bitopic or dualsteric compounds, was 
that of Disingrini et al. (2006); the orthosteric building blocks of the nonselective orthosteric 
muscarinic agonists oxotremorine, oxotremorine-M and related agonists were combined with 
parts of the allosteric modulators W84 and naphmethonium, two subtype-selective allosteric 
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antagonists for the M2 receptor. These compounds showed improved subtype selectivity but no 
gain in affinity compared with their parental molecules.  
Theoretically, a heterobivalent ligand can be distributed across a given receptor population in 
more than one orientation: it can engage both orthosteric and allosteric sites in a dualsteric mode 
(dualsteric binding pose), or it can adopt a different pose that recognizes the allosteric site 
exclusively, while still allowing the orthosteric site to be exposed for interaction with an 
orthosteric ligand (pure allosteric pose). Experimental studies and molecular docking simulations 
conducted with these dualsteric ligands on muscarinic M2 receptors (Bock et al., 2014; Bock et al., 
2016) demonstrated that these hybrid compounds are actually able to bind in two different 
binding poses, concept that is referred to as dynamic ligand binding. It was additionally reported 
that, for compounds carrying an agonistic orthosteric moiety and an inactivating allosteric 
fragment, the combination of inactive and active receptor states in a system resulted in overall 
partial agonism of the studied hybrids. Furthermore, it was shown that the affinity of the 
fragments for the orthosteric and allosteric sites determines the fraction of compound bound in 
one or the other pose (Bock et al., 2014).  
 
1.7 Aim of the thesis 
 
The main aim of this thesis was to investigate whether dualsteric hybrid ligands carrying an 
agonistic orthosteric moiety linked to an antagonistic allosteric moiety may elicit protean agonism 
at the M2 receptor subtype. The basis for this investigative direction was the concept that 
heterobivalent ligands of this kind can adopt two different binding poses, the first leading to 
receptor activation (dualsteric pose) and the second driving to receptor silencing (pure allosteric 
pose). This unique ability of dualsteric compounds leads to a potential scenario in which these 
model derivatives may act as protean agonists (Fig. 1.4): a dualsteric compound which prefers 
binding in an allosteric binding topography will result in inverse agonism in a system with 
pronounced spontaneous receptor activity (red curve). However, if this compound is also able to 
bind in a dualsteric binding pose, functional agonism may occur in a quiescent receptor system 
(blue curve). 
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Figure 1.4: Proposed mechanism of action of dualsteric ligands acting as protean agonists. Dualsteric 
ligands may potentially bind either in a dualsteric binding pose, stimulating receptor signaling, or in a purely 
allosteric pose, inactivating the receptor (Bock et al., 2014). In this sense, dualsteric binding of protean 
agonists may lead to a positive signaling output in an inactive receptor system (hypothetical blue curve), 
whereas the compound may behave as an inverse agonist in a receptor system with spontaneous activity 
(hypothetical red curve).  
 
Therefore, the purposes of this work were, as listed below: 
 To identify the conditions necessary to have two stable receptor systems for the wild type 
M2 receptor, i.e. one showing a low amount of spontaneous activity and the second 
exhibiting high levels of constitutive activity.  
 
 To test in these newly-established systems a set of dualsteric compounds that were 
composed by an orthosteric moiety, endowed with either agonistic or superagonistic 
activity and connected through variable linkers to antagonistic allosteric moieties, in the 
interest of detecting eventual protean agonists.  
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 To identify structure-activity relationships, in order to define the molecular features 
required for protean agonism at M2 receptors among this collection of dualsteric 
compounds. 
 
 To clarify the molecular mechanism eliciting protean agonism at the M2 receptor, with the 
purpose of establishing whether this phenomenon is dependent on the intrinsic efficacy of 
the compound, as speculated in previous reports, or on a new mechanism dictated by the 
heterobivalent nature of these compounds.  
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2. MATERIALS AND METHODS 
 
2.1 Cell culture 
 
Chinese Hamster Ovary (CHO) FlpIn cells stably expressing either the human M2 or the single 
mutant M2422W→A receptor were thawed from the nitrogen tank and rapidly seeded in 15 cm 
culture dishes with Ham’s F12 medium (R30) supplemented with 10% FBS (Fetal Bovine Serum, 
R21), 2 mM L-glutamine (R27), 100 units/ml penicillin, and 100 µg/ml streptomycin (R31). The cells 
were incubated at 37°C, 5% CO2 and 96% humidity until they reached 80-90% of confluence. After 
aspiration of the medium, cells were washed with 10 ml phosphate buffered saline (PBS, R19) to 
remove residual medium and serum proteins. They were detached by addition of 3 ml of trypsin-
EDTA solution (R35). Finally, 7 ml of medium were added to the plate to inactivate trypsin and 1 ml 
of cells was placed in a new dish containing 18 ml of fresh medium and incubated until confluence 
was reached. In order to store backup cells with low passage number, cells were frozen and kept 
in liquid nitrogen. The procedure consisted in harvesting the cells as previously described and 
centrifuging the suspension at 900 rpm for 4 minutes at 4°C. After removal of the supernatant, the 
cells were resuspended in fresh medium supplemented with 10% DMSO (Dimethyl sulfoxide), 
transferred in cryovials (M10) and frozen at -80°C in a container (Mr. FrostyTM, T15) allowing a rate 
of cooling of about -1°C/min. Once the suspension was completely frozen, the cryovials were 
stored in liquid nitrogen.  
 
2.2 Membrane preparation 
 
Cells which had almost reached confluence were exposed to 14 ml of fresh medium supplemented 
with 5 mM sodium butyrate (S1) in order to stimulate overexpression of receptors (Kruh, 1982), 
and incubated for 18-24 hours. 
On the day of preparation, the medium from 5 dishes was aspirated and 2.4 ml of ice-cold 
homogenization buffer (S5) were added to each dish. The cells were then detached with a scraper 
and the cell suspension was transferred into a glass falcon. Afterwards, 6 ml of homogenization 
buffer were used to wash the 5 dishes and the liquid was then added to the same falcon as used 
before. These cycles were done 8 times, for a total of 40 plates.  
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The cells were homogenized with a Polytron homogenizer (T11), with 2 rounds at level 6, the first 
time for 25 seconds and the second time for 20 seconds. The homogenates were centrifuged at 
40,000 g for 10 minutes at 2°C and then the supernatant was discarded. The pellet was washed 
twice, adding 20 ml of centrifugation buffer (S6) to each falcon, re-suspending the pellet by gently 
vortexing and centrifuging with the settings used before. Finally, all the pellets were re-suspended 
in 40 ml of Tris buffer (S13), aliquoted, and stored in the freezer at -80 °C.  
 
2.3 Protein quantification 
 
The protein content of homogenates was determined by the method of Lowry (Lowry et al., 1951). 
The homogenates were first pre-treated with copper ion in alkali solution (S2, S9, S10), and after 
10 minutes of incubation the Folin reagent (S3) was added. The aromatic amino acids in the 
treated sample reduced the phosphomolybdatephosphotungstic acid present in the Folin reagent, 
resulting in a product of the reaction with a blue color. The amount of proteins in the sample 
could be estimated measuring the absorbance at 500 nm of the end product against a standard 
curve of a Human Serum Albumin (HSA, R26) solution.  
 
2.4 Radioligand binding studies 
 
In radioligand binding assays, receptors are incubated with a radiolabeled compound for a certain 
time, usually in the presence of unlabeled ligands or other modulators, and then the label bound 
to the receptor is separated from the unbound ligand, allowing the bound radioligand to be 
quantified. 
There are two components of radioligand-binding: a “specific” component of binding to the 
receptor of interest and a “nonspecific” component of binding to other sites. The nonspecific 
binding is measured in the presence of a concentration of unlabeled ligand sufficient to prevent 
binding of the radioligand to its specific binding site. Specific binding is calculated from the 
difference between total and nonspecific binding. 
Binding studies were used in an attempt to quantify the parameters of drug-receptor interaction 
according to a model of drug action. The simplest model is the Law of Mass Action, in which 
ligands bind reversibly to a single binding site: 
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According to this model, a ligand, L, binds to a receptor, R, with an association rate constant kon, to 
form a ligand-receptor complex, LR, which is stable for a time but eventually dissociates into free, 
unchanged receptor and ligand, with a dissociation rate constant koff. Binding reaches equilibrium 
when the rate of formation of liganded receptor is equal to the rate of dissociation of ligand-
receptor complexes: 
 
 
 
This equation is rearranged to give two equilibrium constants: 
 
 
 
where Kd is the equilibrium dissociation constant, i.e. the concentration of the radioligand that 
results in binding to 50% of the receptors, and 
 
 
 
where Ka is the equilibrium association constant. 
The law of mass action predicts the fractional receptor occupancy at equilibrium as a function of 
ligand concentration. Fractional occupancy is the fraction of all receptors that have bound to the 
radioligand. 
 
 
 
Multiplying both numerator and denominator by [L]/[LR] and substituting the definition of Kd: 
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Equilibrium specific binding (Beq) at a particular radioligand concentration equals fractional 
occupancy times the total receptor number (Bmax): 
 
 
 
2.4.1 Homologous competition binding assays 
 
Homologous competition binding assays have been used to characterize the M2 receptor in 
membrane preparations and to obtain the Kd value of the radiolabeled probe for the calculation of 
the dissociation constant of the orthosteric test compounds (Ki) in heterologous binding 
experiments (see paragraph 2.4.3). 
These experiments are based on the competition between a compound, used in multiple 
concentrations, and its corresponding radiolabelled compound, used in one single concentration; 
in this work the antagonist N-methylscopolamine (NMS), tritiated and unlabelled, was used as 
probe. The aim of these assays is to determine the Kd value as a measure of affinity for NMS, and 
the receptor number (Bmax) in the membrane preparations. 
A computer program is used to plot the obtained values for [3H]NMS-binding on the ordinate 
against the logarithm of the concentration of the competitor on the abscissa. Subsequently, 
nonlinear regression analysis on the basis of the following four parameter logistic function is 
utilized to calculate a sigmoidal curve that fits best to the set of data points: 
 
 
 
where Btot([X]) is [3H]NMS total binding in the presence of a concentration [X] of the inhibitor, Min 
is the lower plateau of the curve ([3H]NMS unspecific binding), Max is the upper plateau of the 
curve ([3H]NMS total binding in the absence of inhibitor), IC50 is the inflection point of the curve 
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([3H]NMS specific binding is reduced by 50% if [X]=IC50) and nH is the Hill slope (a measure of the 
curve steepness). 
This analysis yields three values: the top plateau (Max), which is the total binding of radioligand 
without competitor, the bottom plateau (Min), which is the nonspecific binding of the radioligand, 
and the IC50, which represents the concentration of unlabeled ligand that displaces half the specific 
radioligand binding.  
From these data it is also possible to obtain the specific binding of the radioligand (Beq): 
 
 
 
while the Kd and the Bmax are calculated as follows. 
According to the equation of Cheng and Prusoff (1973): 
 
 
 
in which Kunlabeled and Klabeled are the dissociation constants of the unlabeled and labeled ligand 
respectively, and L is the concentration of radioligand used. The labeled and unlabeled ligands are 
assumed to bind with the same affinity to the receptors, then Klabeled = Kunlabeled = Kd. Substituting in 
(10): 
 
       
 
 
 
 
 
 
According to the law of mass action: 
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Substituting from (13): 
 
 
 
These equations for Kd and Bmax calculations, formulated by DeBlasi et al. (1989), are based on four 
assumptions: that the labeled and unlabeled ligands have identical affinities for the receptor; that 
only one class of binding site exists; that there is no cooperativity between binding sites and that 
only a small fraction of the total ligand is bound to the receptors. 
 
2.4.1.1 Experimental procedure 
 
In the performed assays [3H]NMS was added at the concentration of 0.2 nM. The [3H]NMS was 
used in competition with the unlabeled NMS molecule, in multiple concentrations ranging from 
10-12 to 10-6 M; the nonspecific binding was determined by adding an excess of atropine, in order 
to occupy all the specific binding sites. 
The assays were performed in 96-well plates (M1) either in Tris buffer (S13), Tris NaCl buffer (S14) 
or Tris KCl buffer (S15) at pH 7.4 and incubated for 3 hours in a shaking water bath (T7) at 24°C. At 
the end of the incubation, the plates were filtrated in a TomTec filtration device (T24), through 
glass fibre mats (M14) previously soaked with polyethyleneimine (PEI) solution (S12) for 4-5 
minutes to reduce unspecific binding to the filter material. The filters were then dried in a 
microwave (T18) for 2.5 minutes and transferred to a heating block (T19) after covering them with 
melt-on scintillator sheets (M12). Finally, they were inserted in a plastic protector (M15) and put 
into a cassette (M13). A solid scintillator counter (T30) was used to detect and quantify receptor-
bound [3H]NMS. The reaction mixture is indicated in the table below (Table 2.1): 
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Total 
binding 
(µl) 
Unspecific 
binding 
(µl) 
Competition 
(µl) 
Final 
concentration/well 
NMS - - 50 Variable 
Atropine - 50 - 10 µM 
H20 50 - - - 
GDP 50 50 50 100 µM 
Membranes 100 100 100 30 µg/ml 
Buffer 250 250 250 See above 
[3H]NMS 50 50 50 0.2 nM 
 
Table 2.1: Composition of the homologous competition binding assay 
 
2.4.2 Dissociation binding assays 
 
Dissociation binding assays were performed either to better characterize the kinetic properties of 
the radioligand in the employed buffers, or to analyze an allosteric modulation of the receptor. 
 
2.4.2.1 Complete dissociation 
 
Complete dissociation binding studies were performed with the radioligand [3H]NMS in order to 
calculate the dissociation rate constant k-1 and the half-life of dissociation, which is fundamental 
to estimate the incubation time for reaching equilibrium in heterologous binding experiments.  
In general, a complete dissociation assay is performed in two steps. First, the receptor is pre-
labeled to equilibrium with a concentration of radioligand that provides high initial occupancy, 
and, secondly, the dissociation is induced by the addition of a saturating concentration of 
unlabeled ligand in order to prevent re-binding of the radiolabeled compound. The time course of 
dissociation is analyzed using the following exponential function: 
 
 
 
where [RL] is the ligand-receptor complex at a specific time-point after the beginning of 
dissociation measurement, [RL0] is the ligand-receptor complex at time zero, k-1 is the dissociation 
-1-k t
0[RL] = [RL ]e (16) 
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constant of the radioligand-receptor complex and t is the time after the beginning of dissociation 
measurement. 
The half-life of radioligand dissociation (t1/2) is calculated with 
 
 
 
2.4.2.1.1 Experimental procedure 
 
Complete dissociation binding studies were performed to determine the dissociation half-life of  
[3H]NMS in Tris and Tris NaCl buffer. The assays were performed in 96 well plates. Membrane 
homogenates were incubated with the radioligand [3H]NMS for 90 min in a shaking water bath at 
24oC. The nonspecific binding was determined by adding an excess of atropine. After 90 min of 
incubation, atropine was added at different time points over a course of 90 min to initiate 
radioligand dissociation. The filtration and quantification of radioligand binding were performed as 
described in the previous paragraph (2.4.1.1). The composition of the assay mixture is summarized 
in the table below (Table 2.2):  
 
 
Total 
binding 
(µl) 
Unspecific 
binding 
(µl) 
Dissociation 
(µl) 
Final 
concentration/well 
Atropine - 50 50 10 µM 
H20 50 50 50 - 
GDP 50 50 50 1 µM 
BSA 50 50 50 0.5% 
Membranes 100 100 100 30 µg/ml 
Buffer 200 150 150 See 2.4.1.1 
[3H]NMS 50 50 50 2 nM 
 
Table 2.2: Composition of complete dissociation binding assay 
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2.4.2.2 Two-point kinetic experiments 
 
Two-point kinetic experiments are generally used to prove an allosteric modulation of a receptor, 
demonstrating altered radioligand dissociation in the presence of the allosteric modulator. These 
assays were used to quantify the allosteric potency; the approach is simpler than recording 
complete dissociation curves, and it consists in the measurement of the amount of radioligand 
bound at the start and the amount of residual radioligand bound at a fixed interval after 
dissociation began. 
The residual binding data obtained were then analyzed with a monophasic exponential decay 
model, described by the equation: 
 
 
 
where Bt is the amount of specific binding at the time t, B0 is the amount bound at the beginning, 
and k-1 is the rate constant of dissociation. The EC50,diss, that is the concentration at which 
dissociation is retarded by 50%, has then been determined by fitting the values of k-1 to a 
nonlinear regression curve with variable slope.  
 
2.4.2.2.1 Experimental procedure 
 
The assay was performed in 96-well plates in either Tris or Tris NaCl buffer. At first, a mastermix 
composed of buffer, [3H]NMS and membrane suspensions was prepared and incubated at 24°C to 
reach the formation of the receptor-NMS complex. The unspecific binding was determined by 
adding water, buffer, [3H]NMS, membrane suspensions and an excess of atropine directly in the 
plates, and then incubating them at 24°C for 45 min. Before filtrating, the mastermix was added in 
the wells of total binding (containing only water), control (containing water and atropine), and test 
compounds in water, at 12 and 9 minutes before filtration in case of Tris buffer and at 6 and 3 
minutes before filtration in Tris NaCl buffer. The filtration and quantification of radioligand binding 
were performed as described previously (2.4.1.1). The composition of the assay mixture is 
summarized in the table below (Table 2.3): 
 
-1-k t
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Total 
binding 
(µl) 
Unspecific 
binding 
(µl) 
Dissociation 
(µl) 
Final 
concentration/well 
Ligand - - 50 Variable 
Atropine - 50 50 10 µM 
H20 100 50 - - 
GDP 50 50 50 1 µM 
BSA 50 50 50 0.5% 
Membranes 50 50 50 30 µg/ml 
Buffer 200 200 200 See 2.4.1.1 
[3H]NMS 50 50 50 2 nM 
 
Table 2.3: Composition of the dissociation binding assay 
 
2.4.3 Heterologous competition binding assays 
 
These experiments were used to determine the binding affinity of the tested compounds. The 
binding of unlabeled ligands is measured indirectly, by the reduction in radioligand binding in the 
presence of unlabeled ligand. If the unlabeled ligand interacts competitively with the radioligand, 
then fractional inhibition of radioligand binding can be expressed as: 
 
 
 
where [I] is the concentration of inhibitor, and IC50 is the inhibitor concentration causing 50% 
inhibition of radioligand binding. Just as the inhibitor competes with the radioligand, so the 
radioligand competes with the inhibitor and the IC50 will usually be larger than the dissociation 
constant of the inhibitor. This value is calculated from the IC50 using the equation of Cheng and 
Prusoff (1973): 
50
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where Ki is the dissociation constant of the inhibitor, and [L] and Kd are the concentration and 
dissociation constant, respectively, of the radioligand. 
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Nonlinear regression analysis is used to plot the radioligand binding against the increasing 
concentrations of the competitor. The analysis is based on the four parameter logistic function 
(Eq. 8).  
In case of experiments performed in the presence of allosteric or dualsteric ligands, the influence 
of the allosteric component had to be taken into account during data analysis. Indeed, allosteric 
and dualsteric ligands are able to bind simultaneously with the orthosteric compounds to the 
receptor, influencing their binding reciprocally. The mutual influence between the two ligands is 
termed cooperativity (α) and their simultaneous interaction with the receptor can be depicted by 
the allosteric ternary complex model (ATCM) (Ehlert, 1988): 
 [࡭] + [ࡾ] + [ࡸ]																[࡭] + [ࡾࡸ] 
 
 [࡭ࡾ] + [ࡸ]																							[࡭ࡾࡸ] 
 
In this scheme, KL is the dissociation constant of the radioligand L for its site on the receptor (R), KA 
is the dissociation constant of allosteric compound (A) for its site, and LR and AR represent the 
drug-receptor complexes. At equilibrium, the effect which L has on the affinity of A is equivalent to 
the effect which A has on the affinity of L and this reciprocal interaction is defined as 
“cooperativity”; its magnitude is equivalent to the factor (α) by which the two drugs either 
increase or decrease their respective dissociation constants. Thus, αKA denotes the dissociation 
constant for the binding of A to RL, αKL denotes the dissociation constant for the binding of L to 
AR, and ARL is the resultant ternary complex.  
An allosteric modulator can show positive, negative or neutral cooperativity, namely increasing, 
decreasing or leaving unaffected the affinity of the orthosteric ligand, respectively. Values of α 
between 0 and 1 indicate positive cooperativity, while values of α > 1 demonstrate negative 
cooperativity. When α = 1, the cooperativity is neutral. The following equation was used to 
calculate the affinity according to the ATCM (Ehlert, 1988): 
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where BL([A]) is the specific binding of the orthosteric ligand L in the presence of an allosteric 
ligand with concentration [A]. Notably, BL([A]) = [RL] + [ARL]. B0 is the specific binding of the 
orthosteric ligand in the absence of the allosteric ligand.   
The incubation time to reach the equilibrium in the presence of allosteric and dualsteric ligands 
was calculated from the results of the dissociation experiments, considering that the time taken to 
attain 97% of the final equilibrium value is 5 × t1/2, where t1/2 is the half-life of radioligand 
dissociation in presence of the allosteric ligand. The t1/2 value was calculated according to the 
following equation (Lazareno and Birdsall, 1995): 
 
 
 
where t1/2off is the dissociation half-life of the radioligand under control conditions, [A] is the 
concentration of the allosteric modulator and EC50,diss is the concentration of allosteric modulator 
that retards radioligand dissociation by 50%. 
 
2.4.3.1 Experimental procedure  
 
The heterologous competition binding assays were carried out as previously described in 
paragraph 2.4.1.1, with the difference that the nonlabeled compounds used were the test 
compounds and the reaction mixture contained 100 µM of GDP, to uncouple the receptors from 
their G proteins and thus ensuring monophasic competition curves. 
The reaction composition is illustrated in the table below (Table 2.4): 
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Total 
binding (µl) 
Unspecific 
binding (µl) 
Competition 
(µl) 
Final 
concentration/well 
Ligand - - 50 Variable 
Atropine - 50 - 10 µM 
H20 50 - - - 
GDP 50 50 50 100 µM 
Membranes 100 100 100 30 µg/ml 
Buffer 250 250 250 See 2.4.1.1 
[3H]NMS 50 50 50 0.2 nM 
 
 Table 2.4: Composition of the heterologous competition binding assay 
 
2.5 [35S]GTPγS binding assays 
 
The [35S]GTPγS binding assay was used to measure the level of G protein activation induced by the 
test compounds after the binding to the M2 and the M2422W→A receptors. 
The main advantage of this assay is that it measures a functional consequence of receptor 
occupancy at one of the earliest receptor-mediated events. The assay is based on the mechanism 
of action of G proteins: activation of receptors by an agonist leads to the dissociation of GDP from 
the Gα subunit, allowing GTP to bind to Gα. This leads to the functional dissociation of the Gα-GTP 
and Gβγ subunits, resulting in the activation of their effector systems. The heterotrimer is 
eventually recreated following GTPase activity of the Gα subunit, forming Gα-GDP and so allowing 
Gα and Gβγ to reassociate. Agonist activation increases the rate of guanine nucleotide exchange 
and, therefore, the amount of active Gα-GTP and Gβγ. While this process follows agonist 
occupation of receptor, receptors may also assume active conformations in the absence of agonist 
and so constitutively activate G proteins (Lefkowitz et al., 1993). 
In the [35S]GTPγS binding assay, [35S]GTPγS replaces endogenous GTP and binds to the Gα subunit 
following activation of the receptor to form a Gα-[35S]GTPγS species. Since the γ-thiophosphate 
bond is resistant to hydrolysis by the GTPase of Gα, G protein is prevented from reforming as a 
heterotrimer and thus [35S]GTPγS labeled Gα subunits accumulate in the membrane and can be 
measured by counting the amount of [35S]-label incorporated. 
30 
 
The assay requires the addition of exogenous GDP, because it acts by filling empty nucleotide 
binding sites on the Gα subunit and hence reduces the basal level of [35S]GTPγS binding such that 
agonist-induced exchange of GDP for [35S]GTPγS can be observed (Harrison and Traynor, 2003).  
The [35S]GTPγS assay allows generation of concentration-effect curves and therefore potency 
(EC50) and maximum effect (Emax) measures. However, it has to be taken into account that agonist 
efficacy determined in this assay is not an absolute measure, and it is then necessary to perform 
the experiments with at least one reference compound, preferentially a full agonist, in order to be 
able to discriminate between full and partial agonism activity of the tested compounds. 
 
2.5.1 Experimental procedure  
 
The assay was carried out in 96-well plates, pipetting all the reagents (see Table 2.5) and 
incubating the plates in a water bath for 60 minutes at 24°C. The filtration was performed as 
previously described (see 2.4.1.1), with the exception that the glass fiber filters were deposited in 
distilled water instead of PEI solution. 
 
 
Basal 
binding 
(µl) 
Unspecific 
binding 
(µl) 
Agonist-
induced 
binding (µl) 
Final 
concentration/well 
Ligand - - 50 Variable 
Atropine - 50 - 10 µM 
H20 100 50 50 - 
GDP 50 50 50 1 µM 
BSA 50 50 50 0.5% 
Membranes 50 50 50 40 µg/ml 
Buffer 200 200 200 See 2.4.1.1 
[35S]GTPγS 50 50 50 0.7 nM 
  
Table 2.5: Composition of [35S]GTPγS binding assay 
 
 
 
 
31 
 
2.6 Statistics 
 
In this study, the data were processed by descriptive statistics and summarized. The values were 
described by statistical parameters and graphs. As a measure of central tendency, the arithmetic 
mean ( X ) was used: 
 
 
X : arithmetic mean 
n: number of values 
xi: individual value 
 
As a measure of scatter, the variance (s2) is used; it describes the dispersion of the individual 
values around the mean, and it represents the sum of the squares of the 
deviations from the mean of the individual values divided by the number of degrees of freedom: 
 
 
 
The square root of the variance, named standard deviation (s), indicates the average deviation of 
individual values from the mean: 
 
 
 
In this work, as a measure of scatter, the standard error of the mean (SEM) is used, as a measure 
of accuracy: 
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In the result section, a parameter a determined by measurement is in general indicated as a = X ± 
SEM. 
Statistics was also employed to decide, if the means of two normally distributed data sets were 
equal. This was performed using an independent two sample two-tailed t-test, in which it was 
assumed that the variances of both data sets were identical. This assumption was previously 
validated with an F-test. The level of significance p for all hypothesis tests was chosen as p=0.05. 
The test statistic of the F-test (F) is the ratio of the variances of the two data sets: 
 
 
 
The null hypothesis is s12 = s22 and the alternative hypothesis is therefore s12 ≠ s22, so both 
variances are assumed to be identical. If the calculated F-value was greater than the tabulated 
critical F-value for p, the null hypothesis was rejected. 
In case the number of data sets was equal or superior to three, a one-way ANOVA test was used. 
One-way ANOVA compares three or more unmatched groups, based on the assumption that the 
populations are Gaussian. The result of this analysis is a P value, which tests the null hypothesis 
that data from all groups are drawn from populations with identical means. If the overall P value is 
large, there is no evidence that the means of the data differ. If the overall P value is small, then it 
is unlikely that the differences observed are due to random sampling. Since a simple one-way 
ANOVA does not indicate which means differs from every other mean, the Bonferroni post-test 
was subsequently applied, in order to identify the exact differences throughout the data sets.  
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2.7 Materials 
 
2.7.1 Technical equipment 
 
In this section, the utilized technical equipment is listed. 
 
Beckman Coulter Inc. (Unterschleißheim, Germany) 
T1 Beckman Avanti J-20 XP centrifuge 
T2 φ 390 pH/Temp/mV/ISE Meter 
 
Beckman Instruments (Palo Alto, USA) 
T3 Beckman LS 6500 scintillation counter 
 
Biochrome, Inc. (Cambridge, UK) 
T4 Ultrospec 3300 pro, UV/Vis spectrometer 
 
Brand GmbH & Co KG (Wertheim, Germany) 
T5 Accu-Jet® pipettor 
 
Carl Zeiss Jena GmbH (Jena, Germany) 
T6 Axiovert 25 microscope 
 
Gesellschaft für Labortechnik, mbH (Burgwedel, Germany) 
T7 GFL® shaking water bath 1083, 1086 
 
Heraeus (Hilden, Germany) 
T8 Herasafe® bench HS15, class II 
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H+P Labortechnik GmbH (Oberschleissheim, Germany) 
T9 Variomag® heatable magnetic stirrer 
 
Ika® Works Inc. (Wilmington, USA) 
T10 MS 1 Minishaker 
 
Kinematica AG (Littau-Luzern, Schweiz) 
T11 Polytron homogenizer 
 
Mettler Toledo AG (Greifensee, Schweiz) 
T12 Balances AG204, B2002-S 
 
Millipore GmbH (Schwalbach, Germany) 
T13 Milli-Q® Biocel A10 ultrapure still 
T14 Elix® still 
 
Nalgene Company (Rochester, New York, USA) 
T15 Mr Frosty 5100 Cyro 1 °C freezing container 
 
Scientific Industries Inc. (Bohemia, New York, USA) 
T16 Vortex Genie 2® G-560 E 
 
Scotsman Ice Systems (Bettolino di Pogliano, Milano, Italy) 
T17 Scotsman AF 100 AS-E 230/50/1 ice maker 
 
Sharp Electronics Europe GmbH (Hamburg, Germany) 
T18 Microwave Sharp P611 
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Techne (Duxford, Cambridge, UK) 
T19 Dri-Block® DB2A 
 
ThermoForma Scientific (Marietta, Ohio, USA) 
T20 Thermoforma -80°C fridge 
T21 Thermoforma series II water jacketed CO2-incubator 
 
Thermo Labsystems Oy (Helsinki, Finland) 
T22 Finnpipette® digital pipets different sizes 
T23 Finnpipette® Multistepper pipet 
 
Tomtec Inc. (Hamden, USA) 
T24 Harvester 96© Mach III M (product number: 963-589) 
T25 Harvester 96© Mach III M (product number: 990607010) 
 
Taylor Wharton Hasco GmbH (Husum, Germany) 
T26 Neubauer counting chamber 
T27 Nitrogen tank LS 750 
 
VWR International (Langenfeld, Germany) 
T28 Neubauer counting chamber 
T29 Cover slips 20×26 mm for Neubauer counting chamber 
 
Wallac (Turku, Finland) 
T30 1450-Microbeta Trilux liquid scintillation & luminescence counter 
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2.7.2 Disposables 
 
In this chapter are listed the expendable items and the manufacturers in the left row and their 
product number in the right row. 
 
Abgene House (Epsome, UK)  
M1 96-well microtiterplate, PP AB-0564 
 
Brand GmbH & Co KG (Wertheim, Germany) 
 
M2 Pipet tips 0.5-5.0 ml 
 
 
Fisher Scientific (Schwerte, Germany)  
M3 Scintillation vessel (PE) 21 ml with screw cap 619301 
 
Greiner Bio-One GmbH (Soligen-Wald, Germany) 
 
M4 Cellstar® disposable pipet 10 ml/25 ml 607160/760160 
M5 Falcon tubes, sterile, 15 ml/50 ml 227261 
M6 Tissue culture plate, sterile 100/20 mm 664160 
M7 Tissue culture plate, sterile 145/20 mm 639160 
 
Merck Labor und Chemie Vertrieb GmbH (Bruchsal, Germany) 
 
M8 Syringe filter units (0.22 µM CM membrane; sterile) 5122110 
 
Nalgene Nunc International (Rochester, USA) 
 
M9 Polycarbonate-PC-centrifuge tubes with cap, 50 ml 3138-0050 
M10 Cryogenic vials, 1 ml 50001012 
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Pechiney Plastic Packaging (Menasha, USA)   
M11 Parafilm® M laboratory film PM-996 
  
Perkin Elmer Life Sciences GmbH (Rodgau-Jügesheim, Germany)   
M12 MeltiLexTM A scintillation wax 1450-441 
M13 Plate cassette 1450-105 
M14 Printed filtermat A 1450-441 
M15 Sample bag 1450-432 
  
Sarstedt AG & Co. (Nümbrecht, Germany)  
M16 Cell scraper, sterile, 25 cm 83.1830 
M17 Pipet tips TipOne® 1-200 µl S1111-0006 
M18 Pipet tips TipOne® 101-1000 µl S1111-2020 
  
ThermoForma Scientific (Marietta, Ohio, USA)  
M19 Finnpipette® multistepper pipet tips 1.25 ml, 2.5 ml, 5.0 ml  
 
2.7.3 Reagents 
 
In this section are listed the reagents on the left and the product number on the right. 
 
Acros Organics (Geel, Belgium)  
R1 Sodium butyrate 26319 
R2 Sodium chloride 207790010 
 
AppliChem (Darmstadt, Germany)  
R3 EDTA disodium salt dihydrate A2937,0100 
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Grüssing GmbH (Filsum, Germany)  
R4 Hydrochloric acid (HCl, 1 M)  
 
Merck KGaA (Darmstadt, Germany) 
 
R5 Folin-Ciocalteu phenol reagent 1.09001.0500 
R6 Copper sulfate penta hydrate (CuSO4 × H2O) (MW: 249.7 g/mol) 1.02790.0250 
R7 Sodium carbonate (Na2CO3) (MW: 106.0 g/mol) 1.06392.0500 
  
Millipore GmbH (Schwalbach, Germany)  
R8 Aqua destillata (Elix® system)  
R9 Aqua pro analysi (Milli Q® system)  
 
Perkin Elmer Life Science GmbH (Rodgau-Jügesheim, Germany) 
 
R10 Emulsifier-Safe™ 6013389 
  
Riedel-de Haen (Seelze, Germany)  
R11 Sodium hydroxide (NaOH 1 mol/l) 06213 
 
Roth (Karlsruhe, Germany) 
R12 Hydrochloric acid (HCl 6 mol/l)  
 
 
R13 Potassium Chloride 6791.3 
R14 TRIS Pufferan® 4855.1 
  
Sigma-Aldrich Chemie GmbH (Taufkirchen, Germany)  
R15 Atropine sulfate (MW: 676,8 g/mol) A-0257 
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R16 Bovine Serum Albumine A2153 
R17 Potassium-sodium tartrate tetrahydrate 
(KNaC4H4O6 × 4H2O) (MW: 282.22 g/mol) 
379832 
R18 DL-Dithiothreitol D0632 
R19 Dulbecco’s phosphate buffered saline (DPBS) D-5652 
R20 Ethylenediaminetetraacetic acid (EDTA) E-9884 
R21 Fetal bovine serum (FBS) F-7524 
R22 Guanosine diphosphate (GDP) (C10H15N5O11P2) sodium salt 
(MW: 465 g/mol) 
G-7127 
R23 HEPES sodium salt (MW: 260.3 g/mol) H-7009 
R24 HEPES potassium salt (MW: 276.39 g/mol) H-0527 
R25 HEPES acid (MW: 238.9 g/mol) H-3375 
R26 Human serum albumin A-1653 
R27 L-Glutamine 200mM G-7513 
R28 Magnesium chloride hexahydrate (MgCl × 6H2O) (MW: 302.3 g/mol) P-5379 
R29 N-methyl-D-glucamine (MW: 195.21 g/mol) 66930 
R30 Nutrient mixture F-12 Ham N-4888 
R31 Penicillin-streptomycin solution P-0781 
R32 Polyethylenimine solution (PEI) P-3143 
R33 2-Propanol, 99.5 % (HPLC) 270490 
R34 Sodium Bromide S4547 
R35 Trypsin-EDTA-solution (0.5 g/l Trypsin; 0.2 g/l Na4EDTA) B-4252 
 
2.7.4 Solutions and buffers 
 
S1 Butyrate stock solution (100 mM) 
5.55 g sodium-butyrate (R1) was solved in 500 ml aqua destillata (R8). Storage at 2-8 °C. 
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S2 Cu2SO4 solution 1 % 
1 g copper sulphate pentahydrate (R6) was solved in 100 ml aqua destillata (R8). It was stored at 
room temperature. 
 
S3 Folin-Ciocalteu reagent 
The Folin-Ciocalteu reagent (R5) was diluted 1:3 with aqua destillata (R8). It was stored at room 
temperature. 
 
S4 HEPES stock solution (200 mM) pH 7.4 
8.68 g HEPES sodium salt (R23) and 15.89 g HEPES acid (R25) were solved in 500 ml Aqua destillata 
(R8). The pH was adjusted to 7.4 by the addition of 1 N NaOH (R11). Storage at 2-8°C. 
 
S5 HEPES buffer 1 (20 mM HEPES, 10 mM Na2EDTA) pH 7.4 
50 ml HEPES stock solution (S4) and 50 ml Na2EDTA standard solution (R8) were added to 400 ml 
aqua destillata (R8). Storage at 2-8°C. 
 
S6 HEPES buffer 2 (20 mM HEPES, 0.1 mM Na2EDTA) pH 7.4 
50 ml HEPES stock solution (S4) and 0.5 ml Na2EDTA standard solution (R8) were filled up to 500 
ml aqua destillata (R8). Storage at 2-8°C. 
 
S7 HEPES potassium buffer (12.5 mM HEPES, 12.5 mM MgCl2; 125 mM KCl) pH 7.4 
9.9 g HEPES acid (R25), 5.4 g HEPES salt (R23), 12.7 g magnesium chloride (R28) and 46.6 g 
potassium chloride (R13) were solved in 5000 ml distilled water (R8). The pH was adjusted to 7.4 
with 1 N NaOH (R11). Storage at 2-8 °C. 
 
S8 HEPES low cations buffer (12.5 mM HEPES, 12.5 mM MgCl2) pH 7.4 
9.9 g HEPES acid (R25), 5.4 g HEPES salt (R23) and 12.7 g magnesium chloride (R28) were solved in 
5000 ml distilled water (R8). The pH was adjusted to 7.4 with 1 N NaOH (R11). Storage at 2-8 °C. 
 
S9 KNaC4H4O6 solution 2 % 
2 g potassium-sodium tartrate tetrahydrate (R17) were solved in 100 ml aqua destillata (R8). 
Storage at room temperature. 
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S10 Na2CO3 solution 2 % 
2 g of sodium carbonate (R7) were solved in 100 ml 0.1 N NaOH. 
 
S11 Nutrient mixture F12-Ham 
50 ml fetal bovine serum (R21), 5 ml penicillin-streptomycin solution (R31) and 4 ml glutamine 
solution (R27) were added to 500 ml Ham’s F12 medium (R30). Storage at 2-8°C. 
 
S12 Polyethylenimine solution 
10 g Polyethylenimine solution (R32) was filled up to 507 g with aqua destillata (R8). Storage at 2-
8°C. 
 
S13 Tris buffer 
1.9 g Tris (R14), 0.127 g magnesium chloride (R28), 0.116 g Na2EDTA (R3) and 0.048 g DTT (R18) 
were solved in 250 ml distilled water (R8). The pH was adjusted to 7.4 with 1 M HCl (R4). Storage 
at 2-8 °C. 
 
S14 Tris NaCl buffer 
1.9 g Tris (R14), 0.127 g magnesium chloride (R28), 0.116 g Na2EDTA (R3), 0.048 g DTT (R18)  and 
3.65 g NaCl (R2) were solved in 250 ml distilled water (R8). The pH was adjusted to 7.4 with 1 M 
HCl (R4). Storage at 2-8 °C. 
 
S15 Tris KCl buffer 
1.9 g Tris (R14), 0.127 g magnesium chloride (R28), 0.116 g Na2EDTA (R3), 0.048 g DTT (R18)  and 
4.66 g KCl (R13) were solved in 250 ml distilled water (R8). The pH was adjusted to 7.4 with 1 M 
HCl (R4). Storage at 2-8 °C. 
 
S16 Tris NaBr buffer 
1.9 g Tris (R14), 0.127 g magnesium chloride (R28), 0.116 g Na2EDTA (R3), 0.048 g DTT (R18)  and 
6.43 g NaBr (R34) were solved in 250 ml distilled water (R8). The pH was adjusted to 7.4 with 1 M 
HCl (R4). Storage at 2-8 °C. 
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S17 Tris NMDGCl buffer 
1.9 g Tris (R14), 0.127 g magnesium chloride (R28), 0.116 g Na2EDTA (R3), 0.048 g DTT (R18)  and 
12.2 g NMDG (R29) were solved in 250 ml distilled water (R8). The pH was adjusted to 7.4 with 1 
M HCl (R4). Storage at 2-8 °C. 
 
S18 Tris wash buffer 
30.29 g Tris (R14) and 5.08 g magnesium chloride (R28) were solved in 5000 ml distilled water (R8). 
The pH was adjusted to 7.4 with 6 M HCl (R11). Storage at 2-8 °C. 
 
S19 HEPES incubation buffer (12.5 mM HEPES, 12.5 mM MgCl2; 125 mM NaCl) pH 7.4 
9.9 g HEPES acid (R25), 5.4 g HEPES salt (R23), 12.7 g magnesium chloride (R28) and 36.5 g sodium 
chloride (R2) were solved in 5000 ml distilled water. The pH was adjusted to 7.4 with 1 N NaOH 
(R11). Storage at 2-8 °C. 
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2.7.5 Ligands of the M2 receptor and test compounds 
 
 
Orthosteric agonists 
 
 
Acetylcholine iodide 
Molecular weight: 273.1 g/mol 
Supplier: Sigma-Aldrich Chemie GmbH 
(Steinheim, Germany) 
Product number: A-7000 
Endogenous ligand of the muscarinic receptors. 
 
 
 
 
Iperoxo iodide 
Molecular weight: 324.2 g/mol 
Provided by Prof. Dr. H. Holzgrabe and coworkers 
(University of Würzburg) 
Super-high affinity agonist of muscarinic receptors. 
 
 
 
 
Isox iodide 
Molecular weight: 322.2 g/mol  
Provided by Prof. Dr. H. Holzgrabe and coworkers 
(University of Würzburg) 
Agonist at muscarinic receptors.  
 
 
 
 
Pilocarpine hydrochloride 
Molecular weight: 244.72 g/mol  
Supplier: Sigma-Aldrich Chemie GmbH 
(Steinheim, Germany) 
Product number: P6503 
Partial agonist at muscarinic receptors.  
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OOM iodide 
Molecular weight: 324.16 g/mol 
Provided by Prof. Dr. M. De Amici and coworkers 
(University of Milan) 
Agonist of muscarinic receptors. 
 
Figure 2.1: Description and chemical structure of the employed orthosteric agonists. 
 
 
Orthosteric antagonists 
 
 
N-methylscopolamine bromide 
Molecular weight: 398.3 g/mol 
Supplier: Sigma-Aldrich Chemie GmbH  
(Steinheim, Germany)  
Product number: S-8502 
Inverse agonist of muscarinic receptors. 
 
 
 
Atropine sulfate 
Molecular weight: 676.8 g/mol 
Supplier: Sigma-Aldrich Chemie GmbH  
(Steinheim, Germany)  
Product number: A-0257 
Inverse agonist of muscarinic receptors.   
 
 
 
Figure 2.2: Description and chemical structure of the employed inverse agonists N-methylscopolamine and 
atropine. 
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Dualsteric compounds 
 
 
ALB3 bromide 
Molecular weight: 670.48 g/mol 
Provided by Prof. Dr. M. De Amici  
and coworkers (University of Milan). 
 
 
 
 
ALB4 bromide 
Molecular weight: 720.54 g/mol 
Provided by Prof. Dr. M. De Amici  
and coworkers (University of Milan).  
 
 
 
 
Isox-0-naph chloride 
Molecular weight: 481.97 g/mol 
Provided by Prof. Dr. M. De Amici  
and coworkers (University of Milan).  
 
 
 
 
Isox-4-naph bromide 
Molecular weight: 706.51 g/mol 
Provided by Prof. Dr. M. De Amici  
and coworkers (University of Milan).  
 
 
 
 
Isox-6-naph bromide 
Molecular weight: 734.6 g/mol 
Provided by Prof. Dr. M. De Amici  
and coworkers (University of Milan).  
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Isox-8-naph bromide 
Molecular weight: 762.61 g/mol 
Provided by Prof. Dr. M. De Amici  
and coworkers (University of Milan).  
 
 
 
 
Iper-0-naph chloride 
Molecular weight: 486 g/mol 
Provided by Prof. Dr. H. Holzgrabe  
and coworkers (University of Würzburg). 
 
 
 
 
Iper-4-naph bromide 
Molecular weight: 708.5 g/mol 
Provided by Prof. Dr. H. Holzgrabe  
and coworkers (University of Würzburg). 
 
 
 
 
Iper-6-naph bromide 
Molecular weight: 736.6 g/mol 
Provided by Prof. Dr. H. Holzgrabe  
and coworkers (University of Würzburg). 
 
 
 
 
Iper-8-naph bromide 
Molecular weight: 764.61 g/mol 
Provided by Prof. Dr. H. Holzgrabe  
and coworkers (University of Würzburg). 
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OOM-6-naph bromide 
Molecular weight: 736.6 g/mol 
Provided by Prof. Dr. M. De Amici  
and coworkers (University of Milan).  
 
 
 
 
Isox-6-phth bromide 
Molecular weight: 656.5 g/mol 
Provided by Prof. Dr. H. Holzgrabe  
and coworkers (University of Würzburg). 
 
 
 
 
Iper-6-phth bromide 
Molecular weight: 658.5 g/mol 
Provided by Prof. Dr. H. Holzgrabe  
and coworkers (University of Würzburg). 
 
 
 
OOM-6-phth bromide 
Molecular weight: 682.5 g/mol 
Provided by Prof. Dr. M. De Amici  
and coworkers (University of Milan).  
 
 
 
Figure 2.3: Description and chemical structure of the dualsteric compounds employed in this study. They 
were generously provided by Prof. Dr. M. De Amici and coworkers (Istituto di Chimica Farmaceutica e 
Tossicologica, Universitá degli Studi di Milano, Italy) and Prof. Dr. H. Holzgrabe and coworkers 
(Pharmaceutical and Medicinal Chemistry, University of Würzburg, Germany). 
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Allosteric fragments  
 
 
6-naph bromide 
Molecular weight: 627.49 g/mol 
Provided by Prof. Dr. H. Holzgrabe  
and coworkers (University of Würzburg). 
 
 
 
8-naph bromide 
Molecular weight: 655.49 g/mol 
Provided by Prof. Dr. H. Holzgrabe  
and coworkers (University of Würzburg). 
 
 
 
6-phth bromide 
Molecular weight: 549.4 g/mol 
Provided by Prof. Dr. H. Holzgrabe  
and coworkers (University of Würzburg). 
 
 
 
PCy-6-Et bromide 
Molecular weight: 561.39 g/mol 
Provided by Prof. Dr. M. De Amici  
and coworkers (University of Milan).  
 
 
 
NCy-6-Et bromide 
Molecular weight: 611.45 g/mol 
Provided by Prof. Dr. M. De Amici  
and coworkers (University of Milan).  
 
 
Figure 2.4: Description and chemical structure of the allosteric fragments employed in this study. They 
were generously provided by Prof. Dr. M. De Amici and coworkers (Istituto di Chimica Farmaceutica e 
Tossicologica, Universitá degli Studi di Milano, Italy) and Prof. Dr. H. Holzgrabe and coworkers 
(Pharmaceutical and Medicinal Chemistry, University of Würzburg, Germany). 
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2.7.6 Nucleotides  
 
 
GDP (Guanosine 5’-diphosphate) sodium salt 
Molecular weight: 465.2 g/mol 
Supplier: Sigma-Aldrich Chemie GmbH  
(Taufkirchen, Germany)  
Product number: G-7127 
 
 
 
Figure 2.5: Description and chemical structure of the employed nucleotide GDP. 
 
 
 
2.7.7 Radioactively labeled compounds 
 
 
[3H]N-methylscopolamine chloride 
Molecular weight: 353.8 g/mol 
Specific activity: 84.1 Ci/mol 
Supplier: PerkinElmer Life Sciences (Boston, USA) 
Product number: NET636001MC 
 
 
 
 
[35S]GTPγS 
Molecular weight: 539.2 g/mol 
Specific activity: 1250 Ci/mol 
Supplier: PerkinElmer Life Sciences  
(Boston, USA) 
Product number: NEG030H250UC 
 
 
 
 
Figure 2.6: Description and chemical structure of the employed radiolabeled compounds [3H]N-
methylscopolamine and [35S]GTPγS. 
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2.7.8 Computer software 
 
GraphPad Prism® (Version 5.03; GraphPad® Software, San Diego, USA) 
ChemSketch® (Version 12.01; Advanced Chemistry Development Inc., Toronto, Canada) 
MathType® (Version 6.9b; Design Science Inc., Longbeach, California, USA) 
Microsoft® Word (Version 2010; Microsoft Corporation, Redmond, USA) 
Microsoft® Excel (Version 2010; Microsoft Corporation, Redmond, USA) 
Microsoft® PowerPoint (Version 2010; Microsoft Corporation, Redmond, USA) 
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3 RESULTS 
 
3.1 Determination of the level of spontaneous activity of the wild type M2 receptor 
in different buffers 
 
3.1.1 Sodium ions removal in HEPES buffer does not stimulate spontaneous activity  
 
Generally, Gi-signalling is investigated in  [35S]GTPγS binding experiments performed in HEPES 
sodium buffer containing 100 mM NaCl (S19) supplemented with 10 µM GDP and 40 µg/ml 
membrane proteins, and incubated for 60 min at 30°C (Schrage et al., 2013; Bock et al., 2014). In 
this buffer, the spontaneous activity of the receptor is not reproducible as its level changes 
dramatically within a same set of experiments (Fig. 3.1).  
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Figure 3.1: [35S]GTPγS binding inhibited by 10 µM atropine. Ordinate: percentage of [35S]GTPγS binding, 
normalized on maximum effect elicited by 100 µM ACh (set 100%). 0% corresponds to basal [35S]GTPγS 
binding. The assay was performed in HEPES sodium buffer with an incubation time of 60 minutes at 30°C. 
The bar diagram shows mean ± SEM of single experiments performed in triplicate. *,**,***: significantly 
different (p<0.05, 0.01, 0.001) according to one-way ANOVA with Bonferroni‘s multiples comparison test. 
 
The parameters derived from these experiments are presented in Table 3.1. 
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Day Emax (%) n 
1 -64 ± 1 1 
2 -13 ± 5 1 
3 -42 ± 1 1 
4 3 ± 10 1 
 
Table 3.1: Parameter values derived from Figure 3.1; Emax: maximum level of [35S]GTPγS binding in percent 
normalized on 100 µM ACh, which was set to 100%; n: number of performed experiments. The table shows 
mean values ± SEM of single experiments carried out in triplicate. 
 
Thus, different HEPES buffers were tested, in order to identify the appropriate conditions to 
establish a stable M2 receptor system, which was either always spontaneously active or inactive. 
The constitutive activity of the M2 receptor, revealed with a single concentration of atropine (10 
µM), was quantified in HEPES potassium buffer (S7) and in an HEPES buffer with low cation 
concentration (S8), maintaining the same concentration of membrane protein and GDP, as well as 
identical temperature and incubation time. Even if sodium depletion is known to stimulate 
receptor constitutive activity in several systems (Costa and Herz, 1989; Tian et al., 1994), this was 
not the case for the M2 receptor. Indeed, as shown in Fig. 3.2, 10 µM atropine did not decrease 
[35S]GTPγS binding to a significant level, i.e. the receptor was inactive in both buffers. 
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Figure 3.2: [35S]GTPγS binding induced in the presence of 10 µM atropine. Ordinate: percentage of 
[35S]GTPγS binding, normalized on maximum effect elicited by 100 µM ACh (set to 100%). 0% corresponds 
to basal [35S]GTPγS binding. The assay was performed with an incubation time of 60 minutes at 30°C. The 
bar diagram shows mean ± SEM of 3 experiments performed in triplicate. n.s.: not significantly different 
from basal [35S]GTPγS binding according to a two-tailed t-test. 
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A summary of the parameters derived from the data analysis is presented in Table 3.2. 
 
Buffer Emax (%) n 
HEPES low cations  -6 ± 2 3 
HEPES potassium -9 ± 3 3 
 
Table 3.2: Parameter values derived from Figure 3.2; Emax: maximum level of [35S]GTPγS binding in percent 
normalized on 100 µM ACh which was set to 100%; n: number of performed experiments. The table shows 
mean values ± SEM of 3 independent experiments carried out in triplicate. 
 
Taken together, this system was not appropriate to generate spontaneous M2 receptor activity. 
 
3.1.2 Testing of M2AChR spontaneous activity in different experimental settings 
 
Taken into consideration that a stable spontaneous receptor system could not be obtained in the 
previously applied conditions (see 3.1.1), protein concentration, GDP, incubation time and 
temperature were individually changed in order to test the level of constitutive receptor activity in 
different settings. At first, the concentration of GDP was varied in HEPES potassium buffer, since 
this nucleotide is known to uncouple the receptor from the G protein (Chang and Snyder, 1980; De 
Lean et al., 1980; Lohse et al., 1984; Stiles, 1988) and might therefore have an influence on 
spontaneous activity. As shown in Fig. 3.3, at the GDP concentration of 10 µM (Log[GDP]= -5), the 
level of spontaneous activity was too small to have a measuring window for inverse agonism. 
Contrarily, at 1 µM (Log[GDP]= -6) and 0.3 µM (Log[GDP]= -6.5) of GDP, the constitutive activity 
was increased (i.e. the system was sensitive to atropine), together with the efficacy of the full 
agonist ACh. At lower GDP concentrations, the spontaneous activity was either absent (at 0.1 µM 
GDP (Log[GDP]= -7) as well as without any GDP) or the endogenous agonist was not showing a 
significant efficacy compared to the basal activity of the receptor (at Log[GDP]= -8).  
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Figure 3.3: [35S]GTPγS binding in control conditions (basal) and in the presence of ACh 100 µM and atropine 
10 µM. (A) Ordinate: [35S]GTPγS binding, expressed as counts per minute (cpm). (B) Ordinate: [35S]GTPγS 
binding, corrected on the basal [35S]GTPγS binding of each GDP concentration. Abscissa: concentration of 
GDP. The assay was performed in HEPES potassium buffer with an incubation time of 60 minutes at 30°C. 
The graph shows mean ± SEM of a representative experiment performed in triplicate. 
 
Considering that the previous results indicated 0.3 µM GDP as the ideal concentration to allow 
visualization of both positive and negative agonism, a representative curve for atropine and ACh 
was obtained in HEPES potassium buffer with 0.3 µM GDP. As shown in Fig. 3.4, the resulting 
amount of spontaneous activity was too small to attain a concentration-effect curve for the 
inverse agonist atropine. Apparently, HEPES potassium buffer had the same limitations that the 
previously tested HEPES sodium buffer had, i.e. an unstable level of spontaneous activity that is 
difficult to control. 
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Figure 3.4: Test compound-induced [35S]GTPγS binding to membrane suspensions from FlpIn CHO-M2 cells 
in HEPES potassium buffer supplemented with 0.3 µM GDP. Ordinate: percentage of [35S]GTPγS binding, 
normalized on the effect of 100 µM ACh which was set to 100%. The upper plateau of ACh does not 
significantly differ from 100%. 0% corresponds to the lower plateau (basal [35S]GTPγS binding). Abscissa: 
logarithm of the concentrations of the compounds. The assay was performed with an incubation time of 60 
minutes at 30°C. The graph shows the mean values ± SEM of a representative experiment performed in 
triplicate. Curve fitting: “Four-parameter logistic equation” (Eq. 8). 
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Since the studies in HEPES buffer did not allow the attainment of a stable spontaneously active 
system, a different buffer composition was chosen for testing. Given that several experimental 
papers studying GPCRs constitutive activity and salt influence reported the use of a Tris buffer for 
the experiments (Rosenberger et al., 1980; Hilf and Jakobs, 1989; Malmberg and Mohell, 1995), 
the following [35S]GTPƴS assays were carried out in a low osmolarity Tris buffer (S13) with 10 µM 
GDP. The washing steps in the filtration phase were performed with a Tris washing buffer (S18), as 
described in the literature (Rosenberger et al., 1980; Selley et al., 2000). At first, the concentration 
of membrane proteins was chosen as the variable factor (Fig. 3.5). 
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Figure 3.5: [35S]GTPγS binding in control conditions (basal) and in the presence of ACh 100 µM and atropine 
10 µM. Ordinate: [35S]GTPγS binding, expressed as counts per minute (cpm). Abscissa: concentration of 
membrane proteins. The assay was performed in Tris buffer with 10 µM GDP with an incubation time of 60 
minutes at 30°C. The bar diagram shows mean ± SEM of a representative experiment performed in 
triplicate.  
 
Notably, hardly any difference is observable at the different protein concentrations. As next step, 
the GDP was applied at 1 µM, and different protein concentrations were also investigated (Fig. 
3.6). 
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Figure 3.6: [35S]GTPγS binding in control conditions (basal) and in the presence of ACh 100 µM and atropine 
10 µM in Tris buffer with 1 µM GDP. Ordinate: [35S]GTPγS binding, expressed as counts per minute (cpm). 
Abscissa: concentration of membrane proteins. The assay was performed with an incubation time of 60 
minutes at 30°C. The bar diagram shows mean ± SEM of a representative experiment performed in 
triplicate.  
 
As indicated by the arrow, at 40 µg/ml of protein there appears to be an acceptable measuring 
window for both agonism and inverse agonism. In order to reduce the high counts number, the 
incubation temperature was lowered to 24°C and three different time points (15, 30 and 60 min) 
were tested (Fig. 3.7). 
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Figure 3.7: [35S]GTPγS binding in control conditions (basal) and in the presence of ACh 100 µM and atropine 
10 µM in Tris buffer with 1 µM GDP and 40 µg/ml of membrane proteins. The incubation was performed at 
24°C for 15, 30 and 60 min. Ordinate: [35S]GTPγS binding, expressed as counts per minute (cpm). Abscissa: 
incubation time expressed in minutes. The bar diagram shows mean ± SEM of a representative experiment 
performed in triplicate.  
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As shown in Fig. 3.7, the incubation at a lower temperature (24°C instead of 30°C) reduced the 
total cpm, and allowed a better definition of the differences between basal [35S]GTPƴS binding and 
[35S]GTPƴS binding measured in the presence of atropine and ACh. At each time point, the 
presence of spontaneous activity is notable, but an incubation time of 60 min seems to be the 
ideal time to better amplify the measuring windows for both agonism and inverse agonism.    
Since the cpm were still very high, bovine serum albumin (BSA) was applied at a concentration of 
0.5% and 1% with the objective of reducing the background noise.  
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Figure 3.8: [35S]GTPγS binding in control conditions (basal) and in the presence of ACh 100 µM and atropine 
10 µM in Tris buffer with 1 µM GDP, 40 µg/ml of membrane proteins and a variable concentration of BSA. 
Ordinate: [35S]GTPγS binding, expressed as counts per minute (cpm). Abscissa: concentration of BSA. The 
assay was performed with an incubation time of 60 minutes at 24°C. The bar diagram shows mean ± SEM of 
a representative experiment performed in triplicate.  
 
As reported in Fig. 3.8, adding BSA to the buffer mixture contributed to significantly lower the 
cpm. Since the level of constitutive activity was comparable at 0.5% and 1% of BSA and a better 
agonism window was observed at 0.5% BSA, this latter concentration was elected for the following 
studies. 
 
3.1.3 Addition of a high concentration of salts inhibits the spontaneous activity in Tris buffer  
 
One of the main requirements of this thesis was the establishment of two wild type M2 receptor 
systems that were either spontaneously active or quiescent. Thus, since a constitutive system had 
been settled (see 3.1.2), the following effort was aimed at investigating the conditions required for 
abolishing the low osmolarity Tris buffer-induced constitutive activity. It was known from previous 
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studies (Wu et al., 2012; Zhang et al., 2012; Fenalti et al., 2014; Miller-Gallacher et al., 2014) that 
Na+ acts as negative allosteric modulator for class A GPCRs, contributing to keep the receptor in a 
quiescent state when present at significant concentrations. Hence, this salt, together with other 
salts as KCl and NaBr, and with the osmotically equivalent NMDGCl (Pihlavisto et al., 1998; Barann 
et al., 2004; Billups et al., 2006; Vivo et al., 2006) was tested for its ability to inhibit M2 
spontaneous activity. Figure 3.9 shows that in Tris buffer (S13) 10 µM atropine significantly 
decreased the basal [35S]GTPγS binding of about 50%, demonstrating that the constitutive activity 
of the receptor is stimulated in these conditions, as anticipated from the preliminary studies (see 
3.1.2). 200 mM of NaCl abolished the constitutive activity of the receptor, as understandable from 
the [35S]GTPγS binding elicited in the presence of 10 µM atropine, that was not significantly 
different from basal binding (set at 0%). Accordingly, 200 mM of NaBr had the same effect of 
silencing the receptor, given that this salt also presents sodium as cation. The surprising result was 
that 200 mM of KCl and NMDGCl, that do not contain sodium, were also able to keep the receptor 
in the quiescent conformation (Fig. 3.9). As a consequence, we recognized that every change of 
osmolarity led to an annulment of constitutive activity. 
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Figure 3.9: [35S]GTPγS binding induced by 10 µM atropine in the presence of 200 mM of the indicated salts 
and the molecule NMDGCl. Ordinate: percentage of [35S]GTPγS binding, normalized on maximum effect 
elicited by 100 µM ACh (set 100%). 0% corresponds to basal [35S]GTPγS binding. The assay was performed 
with an incubation time of 60 minutes at 24°C. The bar diagram shows mean ± SEM of 3-7 experiments 
performed in triplicate. ***: p<0.001, significantly different from the value reported in Tris buffer according 
to one-way ANOVA with Bonferroni‘s multiples comparison test. 
 
A summary of the parameters derived from the data analysis is presented in Table 3.3. 
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Buffer Emax (%) n 
Tris  -53 ± 5 7 
Tris NaCl -2 ± 1 7 
Tris KCl -5 ± 4 7 
Tris NaBr -1 ± 3 7 
Tris NMDGCl -6 ± 1 3 
 
Table 3.3: Parameter values derived from Figure 3.9; Emax: maximum level of [35S]GTPγS binding in percent 
normalized on 100 µM ACh which was set to 100%; n: number of performed experiments. The table shows 
mean values ± SEM of 3-7 independent experiments carried out at least in triplicate. 
 
In order to better characterize the influence of NaCl and KCl on the spontaneous activity of the 
M2AChR, receptor activation was investigated at increasing salt concentrations. As shown in Fig. 
3.10, the constitutive activity progressively diminished and was then completely abolished at the 
highest salt concentration (200 mM). Additionally, [35S]GTPγS binding stimulated by the 
endogenous agonist ACh decreased almost equidistant to basal [35S]GTPγS binding, thus 
maintaining the window for agonism measurement constant over the different NaCl 
concentrations (Fig. 3.10A). The same experiment was performed in the presence of increasing 
concentrations of KCl, with very similar outcomes (Fig.3.10B). 
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Figure 3.10: Influence of increasing concentrations of NaCl (A) and KCl (B) on basal [35S]GTPγS binding and 
binding induced by 100 µM ACh and 10 µM atropine. Maximum stimulation induced by 100 µM ACh was 
set to 100%. Maximum inhibition induced by atropine was set to 0%. The assay was performed with an 
incubation time of 60 minutes at 24°C. Data: mean ± SEM of 3-5 independent experiments. 
 
Taken together, these results indicated that NaCl and KCl have similar effect on the level of 
spontaneous activity of the M2 receptor. 
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3.2 Influence of salts and spontaneous activity on orthosteric signaling  
 
3.2.1 NaCl and KCl decrease the potency of ACh, iperoxo, isox and OOM 
 
The influence of NaCl and KCl on signaling stimulated by the orthosteric agonists ACh, iperoxo, isox 
and OOM was evaluated in [35S]GTPγS binding assays, in order to determine an eventual 
modification of agonist activity in the absence or presence of constitutive activity of the receptor. 
As shown in Fig. 3.11, both salts had significant effects on agonist signaling. Both KCl and NaCl 
shifted the inflection point of the curves (pEC50) to lower values, indicating that these monovalent 
cations reduced the agonist potency. Additionally, the effect of NaCl was stronger than that of KCl 
in decreasing the pEC50 values of all agonists (Table 3.4). 
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Figure 3.11: Test compound-induced [35S]GTPγS binding to membrane suspensions from FlpIn CHO-M2 cells 
in the indicated buffers. Ordinate: percentage of [35S]GTPγS binding, normalized on the maximum effect of 
100 µM ACh which was set to 100%. 0% corresponds to the lower plateau (basal [35S]GTPγS binding). 
Abscissa: logarithm of the concentrations of the compounds. The assay was performed with an incubation 
time of 60 minutes at 24°C. The graph shows the mean values ± SEM of 3-7 experiments performed in 
triplicate. Curve fitting: “Four-parameter logistic equation” (Eq. 8). 
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The Emax values also appeared slightly affected, even though there was no statistical significance. 
In case of iperoxo, there was a tendency pointing to higher values upon salt addition, while for isox 
the Emax imperceptibly decreased. There was no difference reported for ACh, since the upper 
plateau of the curve for the endogenous agonist (and reference ligand) was fixed at 100% in all 
buffers. 
 
Compound Buffer pEC50 Emax (%) n 
ACh Tris  7.71 ± 0.13 100 5 
  Tris KCl 6.34 ± 0.06*** 100 4 
  Tris NaCl 5.83 ± 0.04***/a 100 3 
Iperoxo Tris  9.84 ± 0.11 98 ± 6 4 
  Tris KCl 8.51 ± 0.14*** 110 ± 8 5 
  Tris NaCl 7.90 ± 0.09***/a 127 ± 6 3 
Isox Tris  7.75 ± 0.02 118 ± 4 7 
  Tris KCl 6.99 ± 0.10***  109 ± 14  4  
  Tris NaCl 7.08 ± 0.13*** 101 ± 6 5 
OOM Tris  7.25 ± 0.10 102 ± 4 4 
 Tris KCl 6.79 ± 0.11 109 ± 4 4 
 Tris NaCl 6.63 ± 0.16* 107 ± 5 4 
  
Table 3.4: Parameter values derived from Figure 3.11; pEC50: negative common logarithm of the 
concentration of test compound causing a half maximum effect; Emax: maximum level of [35S]GTPγS binding 
in percent normalized on ACh which was set to 100%; n: number of performed experiments. The table 
shows mean values ± SEM of 3-7 independent experiments carried out in triplicate. *,**,***: significantly 
different (p<0.05, 0.01, 0.001) from the value reported in Tris buffer according to one-way ANOVA with 
Bonferroni‘s multiples comparison test. a: significantly different (p<0.05) from the value reported in Tris KCl 
buffer according to one-way ANOVA with Bonferroni’s post test. 
 
Taken together, a lower level of receptor spontaneous activity, achieved with a high osmolarity 
buffer, causes a decrease in potency of the orthosteric full agonists and the superagonist. 
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3.2.2 The spontaneously active system has elevated basal activity and maximum achievable 
activation 
 
We were interested in the nature of the M2 receptor system with high rates of spontaneous 
activity (Tris buffer) in comparison to a quiescent M2 receptor system (Tris supplemented with 200 
mM NaCl or KCl). We hypothesized that high spontaneous M2 activity may either increase the 
basal level of [35S]GTPγS binding without altering the maximum inducible effect of the system (Fig. 
3.12A), or could lead to an increase in basal [35S]GTPγS binding and also a higher potential Emax of 
the system (Fig.3.12B).  
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Figure 3.12: Hypothetical concentration-effect curves in a spontaneously active system (e.g. [35S]GTPyS 
binding in Tris buffer) in comparison to systems without spontaneous activity (e.g. [35S]GTPyS binding in Tris 
buffer supplemented with NaCl or KCl). (A) Option 1: All systems share the same maximum effect 
achievable and differ only in the basal level of receptor activation. (B) Option 2: Not only the basal signaling 
is elevated but also the achievable maximum effect is higher in the spontaneously active system. 
 
To approach these hypotheses experimentally, [35S]GTPγS binding was measured in CHO-M2 
membranes induced by the endogenous agonist ACh (Fig. 3.13A) and the muscarinic superagonist 
iperoxo (Fig. 3.13B) in one system where the receptor was spontaneously active (Tris) and two 
systems where no spontaneous activity was apparent (Tris KCl and Tris NaCl).  
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Fig. 3.13: Test compound-induced [35S]GTPγS binding to membrane suspensions from FlpIn CHO-M2 cells in 
the indicated buffers. Ordinate: [35S]GTPγS binding, normalized on fold over basal binding measured in Tris 
NaCl buffer. Ordinate value = 1 corresponds to the lower plateau in Tris NaCl buffer (basal [35S]GTPγS 
binding in NaCl). Abscissa: logarithm of the concentrations of the compounds. The assay was performed 
with an incubation time of 60 minutes at 24°C. The graph shows the mean values ± SEM of 4-7 experiments 
performed in triplicate. Curve fitting: “Four-parameter logistic equation” (Eq. 8). 
 
Clearly, not only the basal amount of receptor activity was enhanced but also the maximum 
inducible effect of the system (Emax) was increased in the spontaneously active system in 
comparison to the inactive system. This goes in line with the hypothesis that both basal and 
maximal [35S]GTPγS binding are enhanced in a low osmolarity Tris buffer (Fig.3.12B). 
 
3.2.3 NaCl has no influence on pEC50 and Emax of pilocarpine 
 
Pilocarpine is a partial agonist at M2 receptor that is known to bind to the orthosteric binding 
pocket. Gi-signaling stimulated by this ligand was investigated in [35S]GTPγS binding assays in order 
to determine whether orthosteric full agonists and partial agonists are similarly influenced by NaCl 
addition and by the level of spontaneous activity. As shown in Fig. 3.14, neither the potency nor 
the maximum effect of pilocarpine was affected by the addition of NaCl. 
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Figure 3.14: Pilocarpine-induced [35S]GTPγS binding to membrane suspensions from FlpIn CHO-M2 cells in 
the indicated buffers. Ordinate: percentage of [35S]GTPγS binding, normalized on the maximum effect of 
100 µM ACh which was set to 100%. 0% corresponds to the lower plateau (basal [35S]GTPγS binding). 
Abscissa: logarithm of the concentrations of the compounds. The assay was performed with an incubation 
time of 60 minutes at 24°C. The graph shows the mean values ± SEM of 3-5 experiments performed in 
triplicate. Curve fitting: “Four-parameter logistic equation” (Eq. 8). 
 
The partial agonist stimulated about 40% of the maximum effect produced by ACh, which was set 
to 100%. A summary of the parameters derived from the data analysis is presented in Table 3.5. 
 
Compound Buffer pEC50 Emax (%) n 
Pilocarpine Tris  6.72 ± 0.14 42 ± 4 3 
  Tris NaCl 6.41 ± 0.20 42 ± 5 5 
 
Table 3.5: Parameter values derived from Figure 3.14; pEC50: negative common logarithm of the 
concentration of test compound causing a half maximum effect; Emax: maximum level of [35S]GTPγS binding 
in percent normalized on ACh which was set to 100%; n: number of performed experiments. The table 
shows mean values ± SEM of 3-5 independent experiments carried out in triplicate. 
 
Taken together, orthosteric full and partial agonists are differentially influenced by the addition of 
200 mM to the buffer. Indeed, neither the efficacy nor the potency of the partial agonist 
pilocarpine was modified by the salt addition, while the potency of the full agonists was reported 
to be lowered in the presence of NaCl (see 3.2.1).  
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3.2.4 Atropine displays its inverse agonism in the spontaneously active system 
 
Atropine is known as an antagonist or inverse agonist at the muscarinic M2 receptor. To test the 
effect of this ligand in both experimental systems, [35S]GTPγS assays were performed in Tris and 
Tris NaCl buffer. The results of these experiments are shown in Fig. 3.15.  
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Figure 3.15: Atropine-inhibited [35S]GTPγS binding to membrane suspensions from FlpIn CHO-M2 cells in the 
indicated buffers. Ordinate: percentage of [35S]GTPγS binding, normalized on the maximum effect of 100 
µM ACh which was set to 100%. 0% corresponds to basal [35S]GTPγS binding. Abscissa: logarithm of the 
concentrations of the compounds. The assay was performed with an incubation time of 60 minutes at 24°C. 
The graph shows the mean values ± SEM of 3 experiments performed in triplicate. Curve fitting: “Four-
parameter logistic equation” (Eq. 8). 
 
A summary of the parameters derived from the data analysis is presented in Table 3.6. 
 
 
Compound Buffer pEC50 Emax (%) n 
Atropine Tris  7.74 ± 0.23 -62 ± 6 3 
  Tris NaCl n. d. n. d. 3 
 
Table 3.6: Parameter values derived from Figure 3.15; pEC50: negative common logarithm of the 
concentration of test compound causing a half maximum effect; Emax: maximum level of [35S]GTPγS binding 
in percent normalized on 100 µM ACh which was set to 100%; n: number of performed experiments. The 
table shows mean values ± SEM of 3 independent experiments carried out in triplicate. 
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Atropine behaved as an inverse agonist in Tris buffer and as a neutral antagonist in Tris NaCl 
buffer. This result is not unexpected, considering that an inverse agonist is predicted to decrease 
receptor activation in the presence of constitutive activity, but to have no effect if the receptor 
protein is quiescent.  
 
3.3 Influence of salts on orthosteric ligand binding 
 
3.3.1 NaCl decreases the half-life of dissociation of the radioantagonist 
 
The dissociation of [3H]NMS was investigated in complete dissociation binding assays. These 
experiments allow the determination of the half-life of dissociation, providing an indication of the 
speed of dissociation of the radioligand from the receptor. It was previously reported that NaCl 
causes an acceleration of radiagonist dissociation in opioid receptors (Pert and Snyder, 1973). 
Here, we investigated how NaCl influences the radioantagonist dissociation from the M2 receptor. 
As shown in Fig. 3.16, the dissociation kinetics are almost 4-fold faster in Tris NaCl compared to 
Tris buffer. 
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Figure 3.16: Time-effect curves of [3H]NMS dissociation. Ordinate: [3H]NMS specific binding expressed as 
percentage of [3H]NMS binding at time zero. Abscissa: incubation time of [3H]NMS-bound receptors with 
the compound. Data points: mean ± SEM of 3-4 assays performed in triplicate. Curve fitting was performed 
according to equation (16). The dissociation binding assay was conducted in Tris and Tris NaCl buffer and 
incubated at 24°C. 
 
The parameter values obtained with these experiments are summarized in table 3.7. 
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Buffer  t1/2 (min) n 
Tris 5.40 ± 0.44 3 
Tris NaCl 1.50 ± 0.23*** 4 
  
Table 3.7: Parameter values derived from Figure 3.16; t1/2: half-life of radioligand dissociation expressed in 
minutes; n: number of performed experiments. The table shows mean values ± SEM of 3-4 independent 
experiments carried out in triplicate. ***: significant difference to the value reported in Tris buffer (p<0.001). 
 
Thus, the muscarinic M2 system behaves similarly to the opioid receptors, which are also classified 
as class A GPCRs. 
 
3.3.2 NaCl has no effect on NMS affinity and Bmax 
 
Homologous binding experiments performed with radiolabeled and non-radiolabeled [3H]NMS 
were employed to investigate the affinity of the inverse agonist NMS and to estimate the total 
receptor number (Bmax) of the utilized membrane preparations. It is known that NaCl may have an 
influence on the affinity of antagonists for GPCRs. This salt can increase (Malmberg and Mohell, 
1995), decrease (Rosenberger et al., 1980) or leave unaffected (U'Prichard and Snyder, 1978) the 
affinity of antagonists. In order to better characterize the effect that NaCl and KCl have on the 
affinity of NMS, concentration-effect curves were obtained in Tris, Tris KCl and Tris NaCl buffer. As 
shown in Fig. 3.17, the addition of 200 mM KCl or NaCl had no effect on the affinity of NMS.  
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Figure 3.17: Homologous competition binding with 0.2 nM [3H]NMS as tracer. Ordinate: [3H]NMS binding 
expressed as percentage of the [3H]NMS binding in absence of unlabeled NMS. Abscissa: logarithm of the 
concentration of unlabeled NMS. Curve fitting: “Four-parameter logistic equation” (Eq. 8) with constant Hill 
coefficient n= -1. Data points: mean ± SEM of 4 assays performed in triplicate. The experiments were 
carried out in Tris, Tris KCl and Tris NaCl buffer and incubated for 150 min at 24°C.  
 
The total receptor number (Bmax) was calculated with equation (7) and is represented in Fig. 3.18. 
The addition of NaCl and KCl to the Tris buffer did not influence this parameter. The affinity of 
NMS was calculated according to equation (13). 
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Figure 3.18: Bmax values of the same membrane preparation tested in Tris, Tris KCl and Tris NaCl buffer. n.s.: 
not significantly different from Bmax values reported in Tris buffer according to one-way ANOVA with 
Bonferroni’s post test. 
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The parameter values obtained with these experiments are summarized in table 3.8.  
  
 Buffer pKd Bmax (pmol/mg) n 
Tris 9.01 ± 0.09 2.69 ± 0.34 4 
Tris KCl 8.90 ± 0.10 3.14 ± 0.57 4 
Tris NaCl 8.96 ± 0.14 3.12 ± 0.60 4 
 
Table 3.8: Parameter values derived from Figure 3.17 and 3.18; pKd: affinity of NMS for M2 receptor 
calculated with equation (13). Bmax: number of binding sites according to equation (7); n: number of 
performed experiments. The table shows mean values ± SEM of 4 independent experiments carried out in 
triplicate.  
 
These results indicate that 200 mM of NaCl and KCl influence neither NMS affinity nor the number 
of binding sites of the M2 receptors.  
 
3.3.3 NaCl and KCl decrease the affinity of orthosteric full agonists and the superagonist 
 
[3H]NMS equilibrium binding assays were carried out to determine the affinities of the orthosteric 
agonists for the NMS-unoccupied receptor. All ligands completely displaced [³H]NMS, with 
significantly lower affinities upon addition of salts (Figure 3.19). Curve fitting was based on 
equation (8), and the compound’s affinity for the receptor was calculated from the inflection point 
of the concentration-effect curve applying equation (20). 
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Figure 3.19: [3H]NMS equilibrium binding assays. Ordinate: [3H]NMS binding expressed as percentage of 
[3H]NMS binding in absence of compound. Abscissa: logarithm of the concentration of test compounds. The 
experiments were carried out in Tris, Tris KCl and Tris NaCl buffer supplemented with 100 µM GDP and 
incubated for 150 minutes at 24°C. Data points: mean ± SEM of 3-7 assays performed at least in duplicate. 
Curve fitting: “Four-parameter logistic equation” (Eq. 8). 
 
The parameter values obtained with these experiments are summarized in table 3.9.  
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 Compound  Buffer pKi nH n 
ACh Tris  7.04 ± 0.09 -0.70 ± 0.09 5 
  Tris KCl 6.31 ± 0.03*** -1 (-0.88 ± 0.07) 3 
  Tris NaCl 6.53 ± 0.04** -0.89 ± 0.07 4 
Iperoxo Tris  8.58 ± 0.10 -0.61 ± 0.04 6 
  Tris KCl 7.31 ± 0.07*** -1 (-0.88 ± 0.06) 6 
  Tris NaCl 7.58 ± 0.04*** -0.74 ± 0.05 4 
Isox Tris  6.69 ± 0.09 -0.83 ± 0.04 4 
  Tris KCl 5.79 ± 0.14** -1 (-0.83 ± 0.07) 4 
  Tris NaCl 6.12 ± 0.13* -0.66 ± 0.06 4 
OOM Tris  6.31 ± 0.08 -0.77 ± 0.08 7 
 Tris KCl 5.72 ± 0.16** -0.71 ± 0.08 4 
 Tris NaCl 5.50 ± 0.09*** -1.11 ± 0.26 7 
 
Table 3.9: Parameter values derived from Figure 3.19; pKi: negative common logarithm of the dissociation 
binding constant of the test compounds. nH: Hill slope of the curve. If it did not significantly differ from 
unity, a value of -1 was assumed and the exact value reported in brackets; n: number of performed 
experiments. The table shows mean values ± SEM of 3-7 independent experiments carried out in triplicate. 
*, **,***: significant difference to the pKi value reported in Tris buffer (p<0.05, 0.01, 0.001). 
 
Taken together, these data show that receptor spontaneous activity and/or salt concentration 
significantly influence the affinity of all the orthosteric full agonists and the superagonist 
investigated in this study. 
 
3.3.4 NaCl lightly decreases the affinity of pilocarpine 
 
The partial agonist pilocarpine was tested in [3H]NMS equilibrium binding assays in order to 
determine the affinity of this ligand for the NMS-unoccupied receptor. Pilocarpine completely 
displaced [³H]NMS, with an affinity that was slightly lower in Tris NaCl buffer compared to Tris 
buffer (Figure 3.20). Curve fitting was based on equation (8), and the compound’s affinity for the 
72 
 
receptor was calculated from the inflection point of the concentration-effect curve applying 
equation (20). 
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Figure 3.20: [3H]NMS equilibrium binding assays. Ordinate: [3H]NMS binding expressed as percentage of 
[3H]NMS binding in absence of compound. Abscissa: logarithm of the concentration of pilocarpine. The 
experiments were carried out in Tris and Tris NaCl buffer supplemented with 100 µM GDP and incubated 
for 150 minutes at 24°C. Data points: mean ± SEM of 5 assays performed in triplicate. Curve fitting: “Four-
parameter logistic equation” (Eq. 8). 
 
The parameter values obtained with these experiments are summarized in table 3.10.  
 
 Compound  Buffer pKi nH n 
Pilocarpine Tris  5.20 ± 0.05 -1 (-1.12 ± 0.12) 5 
  Tris NaCl 5.53 ± 0.12* -1 (-1.11 ± 0.10) 5 
 
Table 3.10: Parameter values derived from Figure 3.20; pKi: negative common logarithm of the dissociation 
binding constant of pilocarpine. nH: Hill slope of the curve. If it did not significantly differ from unity, a value 
of -1 was assumed and the exact value reported in brackets; n: number of performed experiments. The 
table shows mean values ± SEM of 5 independent experiments carried out in triplicate. *: significant 
difference to the pKi value reported in Tris buffer (p<0.05). 
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3.4 Influence of salts and spontaneous activity on allosteric signaling  
 
3.4.1 Allosteric compounds act either as inverse agonists or neutral antagonists depending on 
the level of spontaneous activity of M2 
 
In order to determine the effects that a constitutively active and an inactive M2 receptor system 
have on signaling stimulated by allosteric molecules, five allosteric ligands were tested in 
[35S]GTPγS binding studies, in both Tris and Tris NaCl buffer. As shown in Fig. 3.21, all the ligands 
were able to reduce [35S]GTPγS binding, acting as inverse agonists in the spontaneously active 
system. Contrarily, they had no effect in the presence of 200 mM NaCl, showing neutral 
antagonism. 
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Figure 3.21: Test compound-induced [35S]GTPγS binding to membrane suspensions from FlpIn CHO-M2 cells 
in the indicated buffers. Ordinate: percentage of [35S]GTPγS binding, normalized on the maximum effect of 
100 µM ACh which was set to 100%. 0% corresponds to the lower plateau (basal [35S]GTPγS binding). 
Abscissa: logarithm of the concentrations of the compounds. The assay was performed with an incubation 
time of 60 minutes at 24°C. The graph shows the mean values ± SEM of 3-5 experiments performed in 
triplicate. Curve fitting: “Four-parameter logistic equation” (Eq. 8). 
 
The parameter values obtained with these experiments are summarized in table 3.11.  
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Compound  Buffer  pEC50 Emax (%) n 
6-naph Tris  5.52 ± 0.20 -68 ± 11 5 
  Tris NaCl n.d. n.d. 4 
8-naph Tris  5.28 ± 0.5  -46 ± 7 3 
  Tris NaCl n.d. n.d. 3 
PCy-6-Et Tris  5.14 ± 0.45  -33 ± 1 3 
  Tris NaCl n.d. n.d. 3 
Ncy-6-Et Tris  5.41 ± 0.04  -41 ± 16 3 
  Tris NaCl n.d. n.d. 3 
6-phth Tris 5.48 ± 0.49 -45 ± 10 3 
 Tris NaCl n.d. n.d. 6 
 
Table 3.11: Parameter values derived from Figure 3.21; pEC50: negative common logarithm of the 
concentration of test compound causing a half maximum effect; Emax: maximum level of [35S]GTPγS binding 
in percent normalized on 100 µM ACh which was set to 100%; n: number of performed experiments. The 
table shows mean values ± SEM of 3-6 independent experiments carried out in triplicate. 
 
These results indicate that all the tested fragments are allosteric antagonists at the M2 receptor.  
 
3.5 Influence of NaCl on allosteric ligand binding 
 
3.5.1 Addition of 200 mM of NaCl decreases the allosteric potency of the allosteric ligands 
 
The tested allosteric compounds are fragments of the dualsteric ligands that were studied in this 
thesis. In order to estimate the allosteric affinity and the influence of NaCl on allosteric 
interactions, dissociation binding studies were performed. It is known from previous literature 
that the action of allosteric agents depends on the ionic composition of the buffer (Ellis et al., 
1991) and, in particular, that the affinity of alkane-bis-ammonium-type compounds is increased in 
low osmolarity buffers (Tränkle et al., 1996; Schröter et al., 2000). These experiments allowed the 
determination of the allosteric potency of the test compounds in both high and low osmolarity, 
analyzing the delay in the dissociation time of the orthosteric radioligand [3H]NMS. 
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The parameter value obtained was the pEC50,diss of the test compounds, i.e. the concentration of 
compound that inhibits the dissociation of the orthosteric radioligand by 50%. This parameter 
reflects the affinity of the test compounds for the radioligand-occupied receptor, i.e. the affinity 
for the allosteric site of the M2 receptor. Fig. 3.22 shows an exemplifying experiment performed in 
Tris buffer at increasing concentrations of the allosteric ligand 6-naph. At increasing 
concentrations of the compound, the dissociation of [3H]NMS is gradually decreased and then 
abolished at the highest tested concentration of allosteric modulator (10 µM).   
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Figure 3.22: Representative array of curves of the delay of [3H]NMS dissociation induced by 6-naph binding 
to M2 receptors orthosterically-bound with [3H]NMS in Tris buffer. Ordinate: [3H]NMS binding in cpm/0.5 
ml. Abscissa: incubation time of [3H]NMS-bound receptors with the compound. 
 
These results are converted in concentration-effect curves showing the dissociation rate constant 
(k-1) calculated for every single concentration of allosteric modulator (Fig 3.23). 
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Figure 3.23: Concentration-effect curves of the delay of [3H]NMS dissociation induced by the test 
compounds. Ordinate: apparent rate constant of radioligand dissociation expressed as percentage of the 
rate constant in absence of compound. Abscissa: logarithm of the numerical value of the concentrations of 
the tested compounds. Data points: mean ± SEM of 3-4 assays performed in duplicate. Curve fitting: “Four-
parameter logistic equation” (Eq. 8). The dissociation binding assay was conducted in Tris and Tris NaCl 
buffer and incubated at 24°C. 
 
Figure 3.23 shows the graphs derived from the two-point kinetic assays with the four allosteric 
ligands. All the tested ligands are able to partially or totally inhibit the dissociation of the 
orthosteric radioantagonist. The addition of 200 mM NaCl to the buffer causes a rightward shift of 
the curves, denoting a decrease in the allosteric affinity of all the compounds.  
The parameter values obtained with these experiments are summarized in table 3.12. 
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Compound Buffer pEC50,diss 
Bottom plateau 
(%) n 
6-naph Tris  6.93 ± 0.38  25 ± 7   3 
  Tris NaCl 6.36 ± 0.08  0 ± 6 3 
8-naph Tris  7.37 ± 0.15  12 ± 3 4 
  Tris NaCl 6.51 ± 0.03
**   2 ± 3 3 
PCy-6-Et Tris  4.46 ± 0.18  15 ± 14  3 
  Tris NaCl  3.09 ± 0.26* 13 ± 24  3 
NCy-6-Et Tris   4.95 ± 0.11 5 ± 3  3 
  Tris NaCl  4.55 ± 0.09* 3 ± 7  3 
 
Table 3.12: Parameter values derived from Figure 3.23; pEC50,diss: negative common logarithm of the 
concentration of test compound causing a half maximum delay of radioligand dissociation; n: number of 
performed experiments. The table shows mean values ± SEM of 3-4 independent experiments performed in 
duplicate. *,**,***: (p<0.05, 0.01, 0.001), significantly different from the value reported in Tris buffer 
according to a two-tailed t-test. 
 
In sum, the allosteric modulators showed a decrease in affinity for the allosteric binding site of M2 
when investigated in the high osmolarity buffer, as expected from previous data reported in 
literature (Tränkle et al., 1996; Schröter et al., 2000). 
 
3.5.2 PCy-6-Et and NCy-6-Et showed negative cooperativity with [3H]NMS  
 
[3H]NMS equilibrium binding assays were carried out to determine the affinities of the allosteric 
compounds for the NMS-unoccupied receptor. The compound’s affinity for the receptor was 
calculated applying equation (22), derived from the ATCM model (Ehlert, 1988).  
As shown above, the allosteric ligands inhibited, at least partially, [3H]NMS dissociation (3.5.1) in 
dissociation studies. Therefore, the incubation time to reach equilibrium was calculated according 
to Lazareno and Birdsall (Eq. 23). For the highest concentrations of PCy-6-Et and NCy-6-Et used in 
the heterologous binding experiments, the calculated incubation time was 5 hours in Tris buffer 
and 1.5 hours in Tris NaCl buffer. An incubation time of 6 hours was therefore applied in both 
buffers. Figure 3.24 shows the displacement curves of PCy-6-Et and NCy-6-Et in the [3H]NMS 
equilibrium binding assays, performed in Tris and Tris NaCl. 
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Figure 3.24: [3H]NMS equilibrium binding assays. Ordinate: [3H]NMS binding expressed as percentage of 
[3H]NMS binding in absence of compound. Abscissa: logarithm of the concentration of test compounds. The 
experiments were carried out in Tris and Tris buffer supplemented with 100 µM GDP and incubated for 6 
hours at 24°C. Data points: mean ± SEM of 3-4 assays performed in triplicate. Curve fitting: “Four-
parameter logistic equation” (Eq. 8). 
 
Both allosteric fragments were able to displace the radioligand. NCy-6-Et reached full [3H]NMS 
displacement in both buffers, while PCy-6-Et only achieved partial displacement. In both buffers 
PCy-6-Et had a similar affinity, while NCy-6-Et lost affinity in Tris NaCl compared to Tris buffer. 
The data obtained from these experiments are summarized in table 3.13. 
 
Compound  Buffer  pKA 
Lower plateau 
(%) nH n 
PCy-6-Et Tris  4.91 ± 0.20 7 ± 2 -1 (-1.02 ± 0.20)  4 
  Tris NaCl 4.42 ± 0.23  10 ± 14 -2.51 ± 2.48 3 
NCy-6-Et Tris   5.98 ± 0.05  6 ± 2 -1.42 ± 0.12 4 
  Tris NaCl 5.77 ± 0.04*    1 ± 3 -1.60 ± 0.21 3 
 
Table 3.13: Parameter values derived from Figure 3.24. pKA: negative common logarithm of the affinity 
values of the test compounds; nH: Hill slope of the curve; if it did not significantly differ from unity, a value 
of -1 was assumed and the exact value reported in brackets. n: number of performed experiments. The 
table shows mean values ± SEM of 3-4 independent experiments performed in triplicate. *: (p<0.05), 
significantly different from the value reported in Tris buffer according to a two-tailed t-test. 
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Altogether, the results indicate that the two allosteric fragments are negative cooperative with 
[3H]NMS. 
 
3.5.3 6-naph and 8-naph showed conflicting results in equilibrium binding studies  
 
[3H]NMS equilibrium binding assays were also carried out to determine the affinities of the 
allosteric compounds 6-naph and 8-naph for the NMS-unoccupied receptor. The incubation time 
to reach equilibrium was calculated according to Lazareno and Birdsall (Eq. 23). For the 
concentrations of the compounds used in the heterologous binding experiments, the highest 
incubation time for reaching equilibrium was 17 hours. Therefore, an incubation time of 18 hours 
was chosen. Figure 3.25 shows the binding curves of 6-naph and 8-naph in Tris and Tris NaCl. 
Notably, the results of these experiments are contradictory. In some assays, the ligands acted as 
positive allosteric modulators, increasing the binding of [3H]NMS (Fig. 3.25A,B). In others, the 
same compounds were negative allosteric modulators, partially displacing [3H]NMS binding (Fig. 
3.25C,D). 
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Figure 3.25: [3H]NMS equilibrium binding assays. Ordinate: [3H]NMS binding expressed as percentage of 
[3H]NMS binding in absence of compound. Abscissa: logarithm of the concentration of test compounds. The 
experiments were carried out in Tris and Tris buffer supplemented with 100 µM GDP and incubated for 18 
hours at 24°C. (A,B): Mean curve of experiments that resulted in enhancement of [3H]NMS binding. (C,D): 
Mean curve of experiments that resulted in decrease of [3H]NMS binding. Data points: mean ± SEM of 2-6 
assays performed in triplicate. Curve fitting: “Four-parameter logistic equation” (Eq. 8). 
 
Given that the compounds are allosteric modulators, data analysis was performed according to 
equation (22). The results indicated that the affinity of 6-naph and 8-naph is significantly higher in 
case they act as positive allosteric modulators (up to 100-times) rather than partial displacers of 
[3H]NMS.  
The data obtained from these experiments are summarized in table 3.14. 
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Compound  Buffer  pKA 
Lower plateau 
(%) 
Upper plateau 
(%) n 
(A) 6-naph  Tris   9.17 ± 0.17 100 ± 2 113 ± 3 3 
  Tris NaCl 9.04 ± 0.40 102 ± 4 130 ± 5* 4 
(B) 8-naph  Tris  8.74 ± 018 100 ± 2 115 ± 2 3 
  Tris NaCl 8.41 ± 0.49 96 ± 4 118 ± 12 2 
(C) 6-naph  Tris  7.18 ± 0.11 58 ± 3 99 ± 3 6 
  Tris NaCl  6.94 ± 0.22 63 ± 7 100 ± 2 6 
(D) 8-naph  Tris   7.03 ± 0.07  52 ± 4  103 ± 2 2 
  Tris NaCl 6.36 ± 0.10* 26 ± 6 100 ± 1 6 
 
Table 3.14: Parameter values derived from Figure 3.25. pKA: negative common logarithm of the affinity 
values of the test compounds; n: number of performed experiments. The table shows mean values ± SEM 
of 2-6 independent experiments performed in triplicate. *,**,***: (p<0.05, 0.01, 0.001), significantly different 
from the value reported in Tris buffer according to a two-tailed t-test. 
 
Taken together, it was not possible to get a uniform result for 6-naph and 8-naph and given the 
results of this set of experiments it cannot be determined whether these compounds are positive 
or negative cooperative with [3H]NMS. 
 
3.6 Influence of salts and spontaneous activity on dualsteric signaling  
 
3.6.1 Iper-X-naph dualsteric ligands show partial or protean agonism 
 
The five test compounds composed by the superagonist iperoxo and a naphmethonium-derived 
allosteric fragment connected with a linker of different length (see 2.7.5), were evaluated in 
[35S]GTPγS binding experiments. These assays were conducted in order to determine potency and 
efficacy of the test compounds in the Gi pathway in the presence and absence of spontaneous 
activity.  
The inflection point of the concentration-effect curve (pEC50) was taken to reflect the potency of 
the compounds, while the maximum effect (Emax) was considered as a measure of intrinsic activity 
or efficacy of the compounds. The known full agonist acetylcholine was evaluated in the same 
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assay to define the maximum effect. A single concentration of atropine (10 µM) was used to 
determine the amount of spontaneous activity of the receptor as this ligand is a full inverse 
agonist and thus it prevents ligand-independent [35S]GTPγS binding. 
As shown in Fig. 3.26, iper-0-naph showed a very peculiar behavior. This ligand was an inverse 
agonist in the presence of spontaneous activity (Tris buffer) and a partial agonist in the absence of 
constitutive activity (Tris NaCl). The results are shown as normalized either on basal [35S]GTPγS 
binding (Fig. 3.26A) or on the value reported in the presence of 10 µM atropine (Fig. 3.26B). The 
parameter data are derived from Fig. 3.26A for better comparison with the other hybrid ligands. 
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Figure 3.26: Iper-0-naph-induced [35S]GTPγS binding to membrane suspensions from FlpIn CHO-M2 cells. 
Abscissa: logarithm of the concentrations of the compounds. Ordinate: percentage of [35S]GTPγS binding, 
normalized on the maximum effect of 100 µM ACh which was set to 100%. (A) 0% corresponds to the lower 
plateau (basal [35S]GTPγS binding). (B) 0% corresponds to the [35S]GTPγS binding in the presence of 10 µM 
atropine. The assay was performed in Tris and Tris NaCl buffer with an incubation time of 60 minutes at 
24°C. The graphs show the mean values ± SEM of 3-6 experiments performed in triplicate. Curve fitting: 
“Four-parameter logistic equation” (Eq. 8). 
 
The other four compounds were partial agonists in both buffers, as shown in Fig. 3.27. 
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Figure 3.27: Test compound-induced [35S]GTPγS binding to membrane suspensions from FlpIn CHO-M2 
cells. Ordinate: percentage of [35S]GTPγS binding, normalized on the maximum effect of 100 µM ACh which 
was set to 100%. 0% corresponds to the lower plateau (basal [35S]GTPγS binding). Abscissa: logarithm of the 
concentrations of the compounds. The assay was performed in Tris and Tris NaCl buffer with an incubation 
time of 60 minutes at 24°C. The graph shows the mean values ± SEM of 3-6 experiments performed in 
triplicate. Curve fitting: “Four-parameter logistic equation” (Eq. 8). 
 
The parameter values derived from Fig. 3.26 and 3.27 are summarized in Table 3.15. 
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Compound Buffer pEC50 Emax (%) n 
Iper-0-naph Tris  5.19 ± 0.31 -32 ± 6 4 
  Tris NaCl 7.73 ± 0.21** 9 ± 2** 3 
Iper-4-naph Tris  8.14 ± 0.27 60 ± 12 3 
  Tris NaCl 7.56 ± 0.10 38 ± 4 3 
Iper-6-naph Tris  8.26 ± 0.26 57 ± 5 3 
  Tris NaCl 7.43 ± 0.47 27 ± 1*** 4 
Iper-8-naph Tris  8.64 ± 0.07 86 ± 6 5 
  Tris NaCl 8.21 ± 0.06** 85 ± 8 3 
ALB4 Tris  8.51 ± 0.14 81 ± 2 6 
  Tris NaCl 7.70 ± 0.07** 65 ± 8* 4 
 
Table 3.14: Parameter values derived from Figure 3.26A and 3.27; pEC50: negative common logarithm of the 
concentration of test compound causing a half maximum effect; Emax: maximum level of [35S]GTPγS binding 
in percent normalized on 100 µM ACh which was set to 100%; n: number of performed experiments. The 
table shows mean values ± SEM of 3-6 independent experiments carried out in triplicate. *,**,***: (p<0.05, 
0.01, 0.001), significantly different from the value reported in Tris buffer according to a two-tailed t-test. 
 
3.6.2 Isox-X-naph dualsteric ligands show distinct patterns of receptor activation 
 
The five test compounds composed by the full agonist isox and a naphmethonium-derived 
allosteric fragment, connected with a linker of different length, were evaluated in [35S]GTPγS 
binding experiments. The aim of these assays was to determine whether there were differences in 
signaling activation in comparison to the corresponding iperoxo-derivatives. 
The compound with a hexamethylene chain, isox-6-naph, showed protean agonism, similarly to 
the already described iper-0-naph hybrid. As shown in Fig. 3.28, it decreased [35S]GTPγS binding in 
Tris buffer and it stimulated [35S]GTPγS binding in Tris NaCl buffer. The results are shown as 
normalized either on basal [35S]GTPγS binding (Fig. 3.28A) or to 10 µM atropine (Fig. 3.28B). The 
parameter data are derived from Fig. 3.28A for better comparison with the other hybrid ligands. 
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Figure 3.28: Isox-6-naph-induced [35S]GTPγS binding to membrane suspensions from FlpIn CHO-M2 cells. 
Ordinate: percentage of [35S]GTPγS binding, normalized on the maximum effect of 100 µM ACh which was 
set to 100%. (A) 0% corresponds to the lower plateau (basal [35S]GTPγS binding). (B) 0% corresponds to the 
maximum inhibition of [35S]GTPγS binding induced by 10 µM atropine. Abscissa: logarithm of the 
concentrations of the compounds. The assay was performed in Tris and Tris NaCl buffer with an incubation 
time of 60 minutes at 24°C. The graph shows the mean values ± SEM of 5-7 experiments performed in 
triplicate. Curve fitting: “Four-parameter logistic equation” (Eq. 8). 
 
The results obtained for the other dualsteric ligands are shown in Fig. 3.29. 
Isox-0-naph was an inverse agonist in the spontaneously active system and a neutral antagonist in 
the quiescent system. Isox-4-naph and isox-8-naph were partial agonists in both systems. Upon 
addition of NaCl to the buffer and decrease of the constitutive receptor activity, the Emax of both 
compounds was significantly reduced. 
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Figure 3.29: Test compound-induced [35S]GTPγS binding to membrane suspensions from FlpIn CHO-M2 
cells. Ordinate: percentage of [35S]GTPγS binding, normalized on the maximum effect of 100 µM ACh which 
was set to 100%. 0% corresponds to the lower plateau (basal [35S]GTPγS binding). Abscissa: logarithm of the 
concentrations of the compounds. The assay was performed in Tris and Tris NaCl buffer with an incubation 
time of 60 minutes at 24°C. The graph shows the mean values ± SEM of 3-5 experiments performed in 
triplicate. Curve fitting: “Four-parameter logistic equation” (Eq. 8). 
 
The parameter values inferred from these experiments are summarized in Table 3.16. 
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Compound Buffer pEC50 Emax (%) n 
Isox-0-naph Tris   4.76 ± 0.35 -56 ± 7   3 
  Tris NaCl n.d. n.d. 3 
Isox-4-naph Tris   7.28 ± 0.03  17 ±3 3 
  Tris NaCl  7.71 ± 0.21*  8 ±2 3 
Isox-6-naph Tris   6.50 ± 0.34  -17 ±4 7 
  Tris NaCl  7.81 ± 0.38** 16 ± 3** 5 
Isox-8-naph Tris   8.38 ± 0.28  58 ± 4 5 
  Tris NaCl  8.02 ± 0.32  22 ± 2*** 3 
 
Table 3.15: Parameter values derived from Figure 3.28 and 3.29; pEC50: negative common logarithm of the 
concentration of test compound causing a half maximum effect; Emax: maximum level of [35S]GTPγS binding 
in percent normalized on 100 µM ACh which was set to 100%; n: number of performed experiments. *,**,***: 
significantly different (p<0.05, 0.01, 0.001) from the value reported in Tris buffer according to a two-tailed 
t-test. The table shows mean values ± SEM of 3-7 independent experiments carried out in triplicate. 
 
3.6.3 OOM-6-naph shows protean agonism at M2 
 
OOM-6-naph is a dualsteric ligand composed of an allosteric moiety derived from naphmethonium 
linked through a 6-methylene linker to an oxotremorine-like orthosteric moiety. This compound 
was tested for receptor activation in order to determine whether it behaved similarly to iper-6-
naph, i.e. as a partial agonist, or similar to isox-6-naph, i.e. a protean agonist. As shown in Fig. 
3.30, OOM-6-naph was able to activate M2 receptors in a quiescent system, while inactivating 
signaling of spontaneously active receptors, thus behaving as a protean ligand. 
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Figure 3.30: OOM-6-naph-induced [35S]GTPγS binding to membrane suspensions from FlpIn CHO-M2 cells. 
Ordinate: percentage of [35S]GTPγS binding, normalized on the maximum effect of 100 µM ACh which was 
set to 100%. (A) 0% corresponds to the lower plateau (basal [35S]GTPγS binding). (B) 0% corresponds to the 
[35S]GTPγS binding in the presence of 10 µM atropine. Abscissa: logarithm of the concentrations of the 
compounds. The assay was performed in Tris and Tris NaCl buffer with an incubation time of 60 minutes at 
24°C. The graph shows the mean values ± SEM of 3-4 experiments performed in triplicate. Curve fitting: 
“Four-parameter logistic equation” (Eq. 8). 
 
The parameter values inferred from Fig. 3.30A are summarized in Table 3.17. 
 
Compound Buffer pEC50 Emax (%) n 
OOM-6-naph Tris  7.22 ± 0.60 -26 ± 5 3 
  Tris NaCl 7.40 ± 0.49 17 ± 4** 4 
 
Table 3.17: Parameter values derived from Figure 3.30A; pEC50: negative common logarithm of the 
concentration of test compound causing a half maximum effect; Emax: maximum level of [35S]GTPγS binding 
in percent normalized on 100 µM ACh which was set to 100%; n: number of performed experiments. The 
table shows mean values ± SEM of 3-4 independent experiments carried out in triplicate. **: significantly 
different (p<0.01) from the value reported in Tris buffer according to a two-tailed t-test. 
 
3.6.4 Iper-X-phth dualsteric ligands show partial agonism in both spontaneously active and 
quiescent system 
 
As previously described, three compounds derived from iperoxo, isox and OOM showed protean 
agonism at M2 receptors. All of the previously tested ligands had the same allosteric fragment, i.e. 
naphmethonium-derived (naph-). Here, dualsteric ligands with a different allosteric moiety, i.e. 
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W84-derived (phth-), were studied for comparison. The aim of these experiments was to 
determine whether phth-compounds could elicit protean agonism as their naph-counterparts. 
The compounds ALB3, iper-6-phth, isox-6-phth and OOM-6-phth were analyzed in [35S]GTPγS 
assays and the results are shown in Fig. 3.31.   
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Figure 3.31: Test compound-induced [35S]GTPγS binding to membrane suspensions from FlpIn CHO-M2 
cells. Ordinate: percentage of [35S]GTPγS binding, normalized on the maximum effect of 100 µM ACh which 
was set to 100%. 0% corresponds to the lower plateau (basal [35S]GTPγS binding). Abscissa: logarithm of the 
concentrations of the compounds. The assay was performed in Tris and Tris NaCl buffer with an incubation 
time of 60 minutes at 24°C. The graph shows the mean values ± SEM of 3-5 experiments performed in 
triplicate. Curve fitting: “Four-parameter logistic equation” (Eq. 8). 
 
All of the compounds were partial agonists in both Tris and Tris NaCl buffers. The iperoxo-derived 
ligands showed a significantly lower potency in Tris NaCl compared to Tris buffer, while the 
potency of isox- and OOM-derivatives were not reported to be different in the two buffers. In 
regard to the efficacy, only the Emax of iper-6-phth was significantly decreased when the high 
osmolarity buffer was applied. The parameter values inferred from these experiments are 
summarized in Table 3.18. 
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Compound Buffer pEC50 Emax (%) n 
Iper-6-phth Tris  7.59 ± 0.04 91 ± 5 4 
  Tris NaCl  6.40 ± 0.38* 60 ± 10* 3 
Isox-6-phth Tris   6.67 ± 0.40 33 ± 5 5 
  Tris NaCl  7.20 ± 0.37 19 ± 5 4 
ALB3 Tris  7.92 ± 0.06 86 ± 5  5 
  Tris NaCl 7.20 ± 0.29* 71 ± 7  5 
OOM-6-phth Tris  7.19 ± 0.29 44 ± 7 5 
 Tris NaCl 7.16 ± 0.45 27 ± 3 5 
 
Table 3.18: Parameter values derived from Figure 3.31 ; pEC50: negative common logarithm of the 
concentration of test compound causing a half maximum effect; Emax: maximum level of [35S]GTPγS binding 
in percent normalized on 100 µM ACh which was set to 100%; n: number of performed experiments. *: 
significantly different (p<0.05) from the value reported in Tris buffer according to a two-tailed t-test. The 
table shows mean values ± SEM of 3-5 independent experiments carried out in triplicate. 
 
3.7 Influence of NaCl on dualsteric ligand binding 
 
3.7.1 Six dualsteric ligands lose allosteric affinity in Tris NaCl buffer  
 
Isox-6-naph, iper-6-naph, iper-8-naph, ALB3 and ALB4 are heterobivalent ligands composed of an 
orthosteric and an allosteric moiety. To check for allosteric interaction, dissociation binding 
studies were performed. The assays were carried out in Tris and Tris NaCl buffer to verify if the 
presence of NaCl had an influence on the allosteric potency of the listed compounds. Fig. 3.32 
shows the results of these experiments. 
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Figure 3.32: Concentration-effect curves of the delay of [3H]NMS dissociation induced by the test 
compounds. Ordinate: apparent rate constant of radioligand dissociation expressed as percentage of the 
rate constant in absence of compound. Abscissa: logarithm of the numerical value of the concentrations of 
the compounds. Data points: mean ± SEM of 3-6 assays performed in duplicate. Curve fitting: “Four-
parameter logistic equation” (Eq. 8). The dissociation binding assay was conducted in Tris and Tris NaCl 
buffer and incubated at 24°C. The bottom plateaus that did not differ significantly from zero were 
constrained to 0.  
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The six dualsteric ligands are able to partially or totally inhibit the dissociation of the orthosteric 
radioantagonist [3H]NMS; all compounds displayed a dose-response curve that was rightward-
shifted in the presence of NaCl, indicating that sodium decreases the allosteric affinity of the 
compounds. 
The parameter values obtained with these experiments are summarized in table 3.19. 
 
Compound Buffer pEC50,diss Bottom plateau (%) n 
Isox-6-naph Tris   8.10 ± 0.11 3 ± 5 3 
  Tris NaCl  6.78 ± 0.22** 4 ± 5 3 
Iper-6-naph Tris   7.31 ± 0.13 1 ± 6 5 
  Tris NaCl  6.75 ± 0.04
***  9 ± 3 4 
Iper-8-naph Tris   7.77 ± 0.21 15 ± 4 3 
  Tris NaCl  6.91 ± 0.04*** 5 ± 3 4 
OOM-6-naph Tris  7.61 ± 0.12 4 ± 3 6 
 Tris NaCl 6.83 ± 0.11*** 2 ± 3 6 
ALB3 Tris  5.14 ± 0.11 9 ± 4 3 
 Tris NaCl 4.05 ± 0.05 13 ± 3 3 
ALB4 Tris  5.98 ± 0.08 1 ± 2  3 
 Tris NaCl 5.06 ± 0.08 0 ± 2 3 
 
Table 3.19: Parameter values derived from Figure 3.32; pEC50,diss: negative common logarithm of the 
concentration of test compound causing a half maximum delay of radioligand dissociation; n: number of 
performed experiments. The table shows mean values ± SEM of 3-6 independent experiments performed in 
duplicate. *,**,***: (p<0.05, 0.01, 0.001), significantly different from Tris buffer according to a two-tailed t-
test. 
 
3.7.2 The allosteric potency of iper-0-naph and isox-8-naph is left unaltered by NaCl addition 
 
Two additional dualsteric ligands were analyzed in dissociation experiments, in order to estimate 
their allosteric potency and an eventual effect of NaCl on their allosteric affinity. As shown in Fig. 
3.33, iper-0-naph and isox-8-naph were able to inhibit the dissociation [3H]NMS, totally and 
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partially, respectively. Upon addition of NaCl, the pEC50,diss was not shifted, pinpointing that NaCl 
had no influence on the allosteric affinity of these two ligands. 
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Figure 3.33: Concentration-effect curves of the delay of [3H]NMS dissociation induced by the test 
compounds. Ordinate: apparent rate constant of radioligand dissociation expressed as percentage of the 
rate constant in absence of compound. Abscissa: logarithm of the numerical value of the concentrations of 
the compounds. Data points: mean ± SEM of 3-4 assays performed in duplicate. Curve fitting: “Four-
parameter logistic equation” (Eq. 8). The dissociation binding assay was conducted in Tris and Tris NaCl 
buffer and incubated at 24°C. The bottom plateaus that did not differ significantly from zero were 
constrained to 0. 
 
The parameter values obtained with these experiments are summarized in table 3.20. 
 
Compound Buffer pEC50,diss Bottom plateau (%) n 
Iper-0-naph Tris  5.95 ± 0.27  -4 ± 7 4 
  Tris NaCl 5.77 ± 0.27  -2 ± 10 3 
Isox-8-naph Tris  7.88 ± 0.10  12 ± 5 4 
  Tris NaCl 7.63 ± 0.03  4 ± 2  4 
 
Table 3.20: Parameter values derived from Figure 3.33; pEC50,diss: negative common logarithm of the 
concentration of test compound causing a half maximum delay of radioligand dissociation; n: number of 
performed experiments. The table shows mean values ± SEM of 3-4 independent experiments performed in 
duplicate. 
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3.7.3 Iperoxo-derived dualsteric hybrids displace [3H]NMS  
 
[3H]NMS equilibrium binding assays were carried out to determine the affinities of the allosteric 
compounds for the NMS-unoccupied receptor. All experiments resulted in monophasic 
concentration-effect curves since they were performed in the presence of 100 µM GDP. Iper-6-
naph, iper-8-naph, iper-0-naph, ALB3 and ALB4 displaced [³H]NMS either partially (iper-6-naph, 
iper-8-naph, iper-0-naph) or completely (ALB3 and ALB4). The compound’s affinity for the receptor 
was calculated applying equation (22), derived from the ATCM model (Ehlert, 1988) or equation 
(20), depending on partial or total radioligand displacement, respectively.  
As shown previously (see 3.7.2), the dualsteric compounds inhibited [3H]NMS dissociation. 
Therefore, the incubation time to reach equilibrium was calculated according to Lazareno and 
Birdsall (Eq. 23). For the highest concentrations of the compounds used in the heterologous 
binding experiments, the incubation time was set to 18 hours for iper-6-naph, iper-8-naph and 
iper-0-naph, given their high allosteric affinity, while an incubation time of 6 hours was chosen for 
ALB3 and ALB4, since these ligands have a lower affinity for the allosteric site. Figure 3.34 shows 
the displacement curves of the iperoxo-derived test compounds in the [3H]NMS equilibrium 
binding assays. 
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Figure 3.34: [3H]NMS equilibrium binding assays with membrane suspensions of CHO-hM2 cells. Ordinate: 
[3H]NMS binding expressed as percentage of [3H]NMS binding in absence of compound. Abscissa: logarithm 
of the concentration of test compounds. The experiments were carried out in Tris or Tris NaCl buffer 
supplemented with 100 µM GDP and incubated for 6 or 18 hours at 24°C. Data points: mean ± SEM of 3-6 
assays performed in triplicate. Curve fitting: “Four-parameter logistic equation” (Eq. 8).  
 
The data obtained from these experiments are summarized in table 3.21. 
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Compound Buffer pKA Hill slope 
Bottom 
plateau (%) n 
Iper-6-naph Tris 7.96 ± 0.08 -1 (-0.93 ± 0.15)  12 ± 3 4 
 Tris NaCl 7.27 ± 0.05*** -1 (-1.09 ± 0.07)  12 ± 2 4 
Iper-8-naph Tris 8.34 ± 0.10 -2.38 ± 0.75 12 ± 1 4 
 Tris NaCl 7.89 ± 0.09* -1 (-1.13 ± 0.36)  13 ± 2 3 
ALB3 Tris 6.24 ± 0.07 -1 (-1.30 ± 0.17)  0 ± 2 3 
 Tris NaCl 6.19 ± 0.18  -1 (-0.87 ± 0.20)  2 ± 2 3 
ALB4 Tris 7.15 ± 0.14  -1 (-1.38 ± 0.11)  -1 ± 1 3 
 Tris NaCl 6.75 ± 0.11 -1 (-1.11 ± 0.14)  -1 ± 1 3 
Iper-0-naph Tris 5.48 ± 0.21 -1 (-1.18 ± 0.14)  28 ± 2 4 
 Tris NaCl 5.96 ± 0.15  -1 (-1.03 ± 0.12)  22 ± 1 6 
 
Table 3.21: Parameter values derived from Figure 3.34. pKA: negative common logarithm of the affinity 
values of the test compounds; nH: Hill slope; if it did not significantly differ from unity, a value of -1 was 
assumed and the exact value reported in brackets. The table shows mean values ± SEM of 3-6 independent 
experiments performed at least in duplicate. *,**,***: (p<0.05, 0.01, 0.001), significantly different from the 
value reported in Tris buffer according to a two-tailed t-test. 
 
3.7.4 Isox- and OOM-derived dualsteric hybrids are positive, neutral or negative cooperative 
with [3H]NMS 
 
[3H]NMS equilibrium binding assays were carried out to determine the affinities of isox- and OOM-
derived compounds for the NMS-unoccupied receptor. The calculated incubation time for the 
highest concentrations of compounds used in these experiments was 17 hours. An incubation time 
of 18 hours was therefore selected. The compound’s affinity for the receptor was calculated 
applying equation (22), derived from the ATCM model (Ehlert, 1988), for isox-6-naph, while it was 
not possible to calculate the affinity of isox-8-naph (incomplete curve) and OOM-6-naph (neutral 
cooperativity with the radioligand) (Fig. 3.35).  
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Figure 3.35: [3H]NMS equilibrium binding assays with membrane suspensions of CHO-hM2 cells. Ordinate: 
[3H]NMS binding expressed as percentage of [3H]NMS binding in absence of compound. Abscissa: logarithm 
of the concentration of test compounds. The experiments were carried out in Tris or Tris NaCl buffer 
supplemented with 100 µM GDP and incubated for 18 hours at 24°C. Data points: mean ± SEM of 3-6 assays 
performed in triplicate. Curve fitting: “Four-parameter logistic equation” (Eq. 8).  
 
The data obtained from these experiments are summarized in table 3.22. 
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Compound Buffer pKA Hill slope 
Bottom 
plateau (%) 
Top plateau 
(%) n 
Isox-6-naph Tris 8.47 ± 0.10 -1 (-1.63 ± 0.62)  100 ± 1 121 ± 3 4 
 Tris NaCl 7.95 ± 0.16* -2.30 ± 1.90  99 ± 3 138 ± 5* 5 
Isox-8-naph Tris 7.91 ± 0.01 n. d. n. d. 100 ± 1 4 
 Tris NaCl 7.71 ± 0.02*** n. d. n. d. 100 ± 2 3 
OOM-6-naph Tris n. d. n. d. n. d. n. d. 6 
 Tris NaCl n. d. n. d. n. d. 100 ± 2 4 
 
Table 3.22: Parameter values derived from Figure 3.35. pKA: negative common logarithm of the affinity 
values of the test compounds; nH: Hill slope; if it did not significantly differ from unity, a value of -1 was 
assumed and the exact value reported in brackets. *,**,***: (p<0.05, 0.01, 0.001), significantly different from 
the value reported in Tris buffer according to a two-tailed t-test. The table shows mean values ± SEM of 3-6 
independent experiments performed in triplicate.  
 
As shown in Fig. 3.35, isox-6-naph enhances radioligand binding both in Tris and Tris NaCl buffer, 
displaying a significantly higher affinity in Tris, but a greater top plateau in Tris NaCl. Concerning 
the ligand isox-8-naph, it appears that this compound decreases [3H]NMS binding, even though it 
is not able to reach a full displacement in the applicable range of concentrations. OOM-6-naph 
showed neutral cooperativity with the radioligand in Tris buffer and slightly negative cooperativity 
in Tris NaCl buffer.   
 
3.8 Determination of the level of spontaneous activity of the single mutant 
M2422W→A receptor in different buffers 
 
The single mutant M2422W→A was described in previous work (Prilla et al., 2006) as an allosteric 
loss-of-affinity mutant (see 1.5.1). Since the influence of the allosteric binding site on the efficacy 
of the test ligands was one of the principal interests in this study, this mutant receptor was tested 
in functional studies. First, the level of spontaneous activity was investigated in Tris and Tris NaCl 
buffer, with the aim of understanding whether these two buffers were able to assure a reliable 
spontaneously active and inactive receptor system, respectively. The results of these experiments 
are shown in Fig. 3.36. 
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Figure 3.36: [35S]GTPγS binding measured in the presence of 10 µM atropine in experiments performed 
either in Tris or Tris NaCl buffer. Ordinate: percentage of [35S]GTPγS binding, normalized on maximum 
effect elicited by 100 µM ACh (set to 100%). 0% corresponds to basal [35S]GTPγS binding. The bar diagram 
shows mean ± SEM of 5-7 experiments performed in triplicate. ***: p<0.001, significantly different from the 
value reported in Tris buffer according to a two-tailed t-test. 
 
The statistical parameters derived from these experiments are listed in table 3.23. 
 
Buffer Emax (%) n 
Tris  -21 ± 4 7 
Tris NaCl 1 ± 1*** 5 
 
Table 3.23: Parameter values derived from Figure 3.35; Emax: maximum level of [35S]GTPγS binding in 
percent normalized on 100 µM ACh which was set to 100%; n: number of performed experiments. The 
table shows mean values ± SEM of 5-7 independent experiments carried out in triplicate. ***: p<0.001, 
significantly different from the value reported in Tris buffer according to a two-tailed t-test. 
 
In Tris buffer the mutant receptor maintains its spontaneous activity, even though at a lower level 
compared to the wild type M2. When the buffer containing 200 mM NaCl was used, the 
spontaneous activity was abolished and the receptor resulted inactivated. 
 
3.9 Influence of NaCl and spontaneous activity on orthosteric signaling at M2422W→A 
 
[35S]GTPγS experiments were performed at the mutant receptor applying increasing 
concentrations of the endogenous agonist ACh, the superagonist iperoxo and the two full agonists 
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isox and OOM. The aim of these experiments was to analyze the differences with the functional 
data reported at the wild type M2. As shown in Fig. 3.37, the potency of ACh and iperoxo is 
decreased when tested in the inactive (Tris NaCl) compared to the active system (Tris). 
Additionaly, iperoxo tends to have an efficacy that surpasses that of ACh in both buffers, even 
though not significantly. The full agonists isox and OOM did not show significant differences in 
potency when they were tested in the quiescent or the spontaneously active system. 
Unexpectedly, the efficacy of isox resulted significantly decreased in Tris NaCl compared to Tris 
buffer. 
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Figure 3.37: Test compound-induced [35S]GTPγS binding to membrane suspensions from FlpIn CHO-
M2422W→A cells in the indicated buffers. Ordinate: percentage of [35S]GTPγS binding, normalized on the 
maximum effect of 100 µM ACh which was set to 100%. 0% corresponds to the lower plateau (basal 
[35S]GTPγS binding). Abscissa: logarithm of the concentrations of the compounds. The assay was performed 
with an incubation time of 60 minutes at 24°C. The graph shows the mean values ± SEM of 3-5 experiments 
performed in triplicate. Curve fitting: “Four-parameter logistic equation” (Eq. 8). 
 
The statistical parameters derived from these experiments are listed in table 3.24. 
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Compound Buffer pEC50 Emax (%) n 
ACh Tris  5.95 ± 0.06 100 ± 1 3 
  Tris NaCl 5.29 ± 0.18* 100 ± 2 3 
Iperoxo Tris  8.29 ± 0.10 121 ± 9 5 
  Tris NaCl 7.53 ± 0.20** 114 ± 10 5 
Isox Tris  6.23 ± 0.42 116 ± 13 3 
 Tris NaCl 6.62 ± 0.51 68 ± 3*/aa 3 
OOM Tris  6.19 ± 0.10 96 ± 11 3 
 Tris NaCl 5.82 ± 0.36 116 ± 11 3 
 
Table 3.24: Parameter values derived from Figure 3.37; pEC50: negative common logarithm of the 
concentration of test compound causing a half maximum effect; Emax: maximum level of [35S]GTPγS binding 
in percent normalized on 100 µM ACh which was set to 100%; n: number of performed experiments. The 
table shows mean values ± SEM of 3-5 independent experiments carried out in triplicate with FlpIn CHO-
M2422W→A cells. *,**,***: (p<0.05, 0.01, 0.001), significantly different from the value reported in Tris buffer. 
a,aa,aaa:  (p<0.05, 0.01, 0.001), significantly different from the value reported for ACh. 
 
3.10 Influence of NaCl and spontaneous activity on dualsteric signaling at M2422W→A 
 
Gi-signaling induced by the dualsteric ligands at the single mutant M2422W→A was investigated in Tris 
and Tris NaCl buffer to better elucidate the influence of a functional allosteric vestibule for 
protean agonism at M2. As shown in Fig. 3.38, all the tested compounds were partial agonists at 
the mutant receptor, including isox-6-naph, iper-0-naph and OOM-6-naph, which were protean 
agonists at the wild type M2AChR. 
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Figure 3.38: Test compound-induced [35S]GTPγS binding to membrane suspensions from FlpIn CHO-
M2422W→A cells in the indicated buffers. Ordinate: percentage of [35S]GTPγS binding, normalized on the 
maximum effect of 100 µM ACh which was set to 100%. 0% corresponds to the lower plateau (basal 
[35S]GTPγS binding). Abscissa: logarithm of the concentrations of the compounds. The assay was performed 
with an incubation time of 60 minutes at 24°C. The graph shows the mean values ± SEM of 3-6 experiments 
performed in triplicate. Curve fitting: “Four-parameter logistic equation” (Eq. 8). 
 
The parameter values derived from these experiments are summarized in table 3.25. 
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Compound Buffer pEC50 Emax (%) n 
Iper-6-naph Tris  7.79 ± 0.08 94 ± 15 6 
  Tris NaCl 7.16 ± 0.21* 97 ± 9 6 
Iper-8-naph Tris  8.65 ± 0.31 104 ± 3 4 
  Tris NaCl 8.26 ± 0.42 82 ± 8* 4 
Isox-6-naph Tris  6.82 ± 0.27 68 ± 2 3 
 Tris NaCl 6.84 ± 0.26 36 ± 6** 4 
Isox-8-naph Tris  7.52 ± 0.47 71 ± 4 3 
 Tris NaCl 7.09 ± 0.38 55 ± 10 4 
OOM-6-naph Tris  7.28 ± 0.11 62 ± 9 3 
 Tris NaCl n.d. n.d. 4 
Iper-0-naph Tris  6.73 ± 0.10 57 ± 7 3 
 Tris NaCl 7.31 ± 0.53 37 ± 7 3 
 
Table 3.25: Parameter values derived from Figure 3.38; pEC50: negative common logarithm of the 
concentration of test compound causing a half maximum effect; Emax: maximum level of [35S]GTPγS binding 
in percent normalized on 100 µM ACh which was set to 100%; n: number of performed experiments. The 
table shows mean values ± SEM of 3-6 independent experiments carried out in triplicate with FlpIn CHO-
M2422W→A cells. *,**,***: (p<0.05, 0.01, 0.001), significantly different from the value reported in Tris buffer; 
n.d.: not determined. 
 
In conclusion, these data show that the single mutation of a residue involved in allosteric 
modulator’s binding causes a dramatic change in signaling of the dualsteric protean ligands, 
confirming the importance of a functional allosteric site in evoking protean agonism.  
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4 DISCUSSION 
 
4.1 The spontaneous activity of the M2 receptor can be fine-tuned by buffer 
osmolarity  
Protean ligands induce opposing effects (Emax) depending on the level of spontaneous activity of a 
G protein-coupled receptor. This phenomenon was first reported in 1995 (Kenakin, 1995a) and is 
based on the assumption that ligand–bound GPCRs may adopt not only one (fully) active and one 
inactive conformation, but also intermediate conformations engendering intermediate intrinsic 
efficacies for activation of intracellular signaling pathways. In this regard, receptor species with a 
lower efficacy than the spontaneously active one yield positive signaling in the presence of 
quiescent receptors and negative signaling when the majority of receptors is constitutively active 
(Kenakin, 1997, 2001; Chidiac, 2002).  
Experimentally, the discovery of protean ligands remains challenging for two reasons, i.e. the lack 
of (i) stable and reliable spontaneously active systems for several GPCRs and (ii) strategies for the 
rational design of this class of agonists. Furthermore, studies which identified protean agonists by 
comparison of agonist-induced signaling in two different functional assay systems may be 
compromised by biased signaling (Jansson et al., 1998; Gbahou et al., 2003). Therefore, two 
experimental systems which differ only in the amount of spontaneous activity are essential for the 
identification of protean agonists. To this end, several strategies have been employed to study 
agonism in the presence and absence of spontaneously active receptors. For instance, 
constitutively activating receptor mutations (Ganguli et al., 1998; Fathy et al., 1999; Pauwels et al., 
2002), an increased expression of receptor/G protein (Jakubík et al., 1998), or a change in buffer 
composition (Newman-Tancredi et al., 2003), have been applied.  
 
Here, we choose to alter M2 wild type receptor activity by a variation of the buffer ingredients. At 
first, sodium ions, which previous studies demonstrated responsible for keeping class A GPCRs in 
an inactive conformation (Liu et al., 2012; Katritch et al., 2014), were either substituted with 
potassium ions or removed in HEPES buffer (see 3.1.1 and 3.1.2). Since none of these tested 
conditions led to a spontaneously active receptor system, a Tris buffer with varying concentrations 
of GDP was tested at different incubation times and temperatures and at variable membrane 
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protein and BSA concentrations. At the end of this part of the study, we recognized that 
[35S]GTPƴS experiments performed in Tris buffer with 1 µM GDP, 40 µg/ml membrane proteins 
and 0.5% BSA incubated for 60 minutes at 24°C assured a stable level of spontaneous activity (see 
3.1.2). Since a quiescent AChM2R system was another requirement for investigating protean 
agonism, high concentrations of NaCl were applied and found to abolish spontaneous activity of 
the receptor, as expected. Accordingly, a high concentration of NaBr also diminished constitutive 
activity. Surprisingly, also high concentrations of KCl and NMDGCl were able to reduce 
spontaneous receptor activity, even though both of them do not contain Na+. Thus, the obtained 
results indicate that inactivation of the M2AChR by a high concentration of sodium ions depends 
on high buffer osmolarity rather than on the salt composition.  
 
4.2 Dualsteric compounds with specific molecular features act as protean agonists 
at M2 
 
In the previous chapter, it was shown that spontaneous activity of the muscarinic M2 receptor can 
reliably be titrated by changing the osmolarity of the buffer in CHO-M2 [35S]GTPγS binding assays.  
To test whether dualsteric ligands could promote protean agonism at this receptor, a set of 14 
hybrid compounds, combining three orthosteric moieties and five allosteric fragments connected 
via different linker length spacers, were chosen for testing in spontaneously active and quiescent 
M2 receptor systems. Three dualsteric ligands, namely iper-0-naph, isox-6-naph, and OOM-6-naph 
(see 2.7.5), were found to be protean agonists, since they acted as inverse agonists in the 
presence of spontaneous activity (Tris buffer) and as partial agonists at the quiescent receptor 
(Tris NaCl buffer).    
 
4.2.1 Reasons for exclusion of iper-0-naph from structure-activity relationship analysis of M2 
dualsteric protean agonists 
 
In order to understand the structure-activity relationships that make a dualsteric compound a 
protean agonist, the common molecular features of the protean ligands were analyzed. At first, 
we decided to exclude iper-0-naph from this analysis, because this compound presents no linker, 
and it is thus too short to bind simultaneously to the allosteric and orthosteric sites of the 
receptor, that according to crystallographic studies are at about 15 Å of distance (Dror et al., 
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2013). Most likely, iper-0-naph binds either to the orthosteric site or to the allosteric site, one at a 
time, but cannot adopt the two binding poses that are required for assuring dynamic ligand 
binding, which we hypothesized as the possible mechanism eliciting dualsteric protean agonism 
(see 1.7). The compounds comprising a hexamethylene linker of about 9 Å, such as isox-6-naph 
and OOM-6-naph, on the other hand, are able to engage both sites on the receptor, as recently 
confirmed by molecular docking simulations with C6-linker ligands (Bock et al., 2016). The 
molecular structures that are shared by both OOM-6-naph and isox-6-naph are a linker of six 
carbons atoms and a naphmethonium-derived allosteric moiety (Fig. 4.1).  
 
 
Figure 4.1: Comparison of the chemical structures of the two protean agonists isox-6-naph and OOM-6-
naph. 
 
4.2.2 Relevance of the orthosteric moiety’s affinity and efficacy for protean agonism 
 
The two protean agonists OOM-6-naph and isox-6-naph differ from the partial agonist iper-6-naph 
only for their orthosteric moiety. Interestingly, when we compare the partial agonist iper-6-naph 
with the protean agonist isox-6-naph, it is notable that the removal of only a double bond in the 
heterocycle causes a switch from partial to protean activity (Fig. 4.2). 
 
 
Figure 4.2: Comparison of the chemical structures of the partial agonist iper-6-naph and the protean 
agonist isox-6-naph. 
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Since we were interested in the molecular explanation for this result, pharmacological 
characterization of the three orthosteric fragments iperoxo, isox and OOM was performed in Tris 
and Tris NaCl buffer. All the orthosteric ligands were full agonists in both buffers (see 3.2.1), with a 
maximum effect that did not significantly differ from the one measured with the endogenous 
agonist ACh. Notably, iperoxo, which is classified as an M2 superagonist (Schrage et al., 2013), had 
a potency (pEC50) that was up to 390-times higher in Tris and up to 19-times higher in Tris NaCl in 
comparison to the pEC50 values of isox and OOM. Additionally, in equilibrium binding studies, the 
superagonist had an affinity up to 180-times higher in Tris and 120-times higher in Tris NaCl when 
compared to isox and OOM (Fig. 4.3). 
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Figure 4.3: Comparison of pKi and pEC50 of the test compounds in Tris and Tris NaCl. pKi: negative common 
logarithm of the dissociation binding constant of the test compounds; pEC50: potency of the compounds in 
[35S]GTPƴS assays. The bar diagrams show mean value + SEM of 3-7 independent experiments carried out in 
triplicate. **,***: (p<0.01, 0.001), significantly different from the value reported for iperoxo according to one-
way ANOVA with Bonferroni post-test. 
 
Taken together, the affinity and potency of the orthosteric moiety of the dualsteric compounds 
are determinant in eliciting protean agonism. Specifically, these data suggest that a dualsteric 
protean agonist should comprise an orthosteric fragment with full agonist, but not superagonist, 
activity at the AChM2R. 
 
4.2.3 Relevance of the allosteric moiety’s steric hindrance for protean agonism 
 
Dualsteric ligands evaluated in this thesis are composed of three main blocks, i.e. an orthosteric 
moiety with agonistic properties, an allosteric fragment able to inactivate the receptor (Fig. 3.21), 
and a linker of different length. Once we established the characteristics required to the orthosteric 
moiety for engineering dualsteric protean agonists, we wanted to determine the structural 
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elements required by the allosteric fragment for being embedded in a dualsteric protean ligand. 
OOM-6-naph and isox-6-naph share the same allosteric fragment, which is derived from the 
allosteric modulator naphmethonium. Interestingly, the corresponding dualsteric compounds 
formed by a W84-derived allosteric moiety (OOM-6-phth and isox-6-phth), although stimulating a 
comparable amount of [35S]GTPƴS binding in Tris NaCl, did not act as inverse agonists in the 
spontaneously active system (Fig. 4.4), thus they do not behave as protean ligands.  
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Figure 4.4: Comparison between the Emax of the protean agonists isox-6-naph and OOM-6-naph with the 
dualsteric ligands embedding a less voluminous allosteric moiety, i.e. isox-6-phth and OOM-6-phth, in Tris 
and Tris NaCl. The bar diagrams show means ± SEM of 4-7 independent experiments performed in 
triplicate. n.s.: not significant. ***: (p<0.001), significantly different according to one-way ANOVA with 
Bonferroni’s post-test. 
 
This result indicates that a bulky residue, i.e. the sterically demanding 1,8-naphthalimide moiety, is 
superior to the less voluminous phthalimide analog in stimulating protean agonism of the 
derivative compounds. Unfortunately, even though it would be interesting to make considerations 
also regarding the affinity of the allosteric fragments in the two buffer systems, this is not feasible, 
due to the contradictory results obtained with the allosteric modulator 6-naph in equilibrium 
binding studies (see 3.5.3). Indeed, the allosteric modulator 6-naph, as well as 8-naph, either 
increased or decreased [3H]NMS binding in the same assay system, hampering an univocal 
conclusion regarding cooperativity and affinity of these modulators. Accordingly, previous work 
also reported conflicting results regarding 6-naph, which was described either as positive 
cooperative with [3H]NMS (Bock et al., 2014) or negative cooperative with the same radioligand 
(Vogel, Dissertation, 2015).  
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4.2.4 Importance of a hexamethylene linker for engineering protean agonism at M2 
 
The linker between orthosteric and allosteric moiety of muscarinic dualsteric ligands was the last 
variable analyzed in order to clarify the structure-activity relationships that allow a dualsteric 
ligand to be a protean agonist. The importance of linker length in eliciting a peculiar signaling 
profile was already demonstrated by a paper from Bock et al. (2012), where it was shown that 
compounds presenting a hexamethylene linker were able to stimulate Gi-biased signaling at the 
M2 receptor, while one ligand with an octamethylene linker did not show any bias. As expected, 
different linker lengths led to different signaling profiles within the set of dualsteric ligands 
examined. Only a C6 chain, of about 9 Å, resulted in compounds eliciting  protean agonism, while a 
slightly shorter linker (C4,  ̴6.5 Å) and a longer one (C8,  ̴11.5 Å) resulted in ligands that were only 
partial agonists in both buffers (see 3.6.2 and 3.6.3). One explanation for this result may be that 
dualsteric compounds with a C6 linker lead to stronger restriction in the flexibility of the allosteric 
binding site of the receptor protein than a C8 linker chain (Bock et al., 2012). Moreover, it has 
been shown that the purely allosteric binding pose of C8 ligands is less stable than that of the C6 
ligands (Bock et al., 2016). Regarding the C4 linkers, molecular docking studies would be needed to 
confirm whether they are able to bind simultaneously to the two binding sites or whether their 
linker is too short to adopt a dualsteric pose. 
 
In conclusion, only slight alterations of the three chemical moieties were sufficient to shift the 
profile of two dualsteric compounds from protean agonism to “classical” partial agonism. The 
molecular features required for protean agonism at the muscarinic M2 receptor were elucidated 
and they are: an orthosteric moiety endowed with an acetylcholine-like efficacy, a bulky allosteric 
moiety to impair the flexibility of the extracellular loop area, and a flexible linker chain of 6 carbon 
atoms (Fig. 4.1). 
 
4.3 Dualsteric ligands uncover a new molecular mechanism eliciting protean 
agonism 
Up until now, protean agonism was thought to reside in the intrinsic efficacy of a ligand (Kenakin, 
1997). Our results point to an additional mechanism that may underlie this phenomenon at GPCRs 
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in case a ligand can simultaneously occupy both the binding site for the endogenous messenger 
and an allosteric binding site of the receptor protein. These dualsteric compounds may bind to a 
receptor protein in two distinct binding modes (Bock et al., 2014; Bock et al., 2016): a purely 
allosteric and a dualsteric mode (Fig. 1.4) and may thus have two distinct efficacies for receptor 
activation. The findings presented here go in line with the idea that the two protean agonists isox-
6-naph and OOM-6-naph prefer binding in the purely allosteric binding pose, as has already been 
demonstrated for isox-6-naph in a previous study (Bock et al., 2014). Both compounds display 
functional inverse agonism under conditions in which the M2 receptor displays a substantial 
amount of spontaneous activity (Fig. 3.28 and 3.30). However, at least under conditions in which 
the receptor does not display any spontaneous activity, a significant fraction of receptors must be 
bound in a dualsteric binding pose, as we observed functional agonism in the quiescent M2 
system. This indicates dynamic ligand binding as the molecular mechanism of protean agonism of 
isox-6-naph and OOM-6-naph. At this point, the question was whether the compounds swapped 
their binding poses in the different buffers. To better clarify this issue, radioligand binding 
experiments were performed and the allosteric binding affinity of several dualsteric ligands was 
investigated. The allosteric affinity of isox-6-naph was 20-times higher in Tris than in Tris NaCl 
buffer, whereas the orthosteric building block isox gained only 3.5-fold in affinity under these 
conditions (Fig. 3.32 and 3.19). We assume that the affinities of the allosteric and of the 
orthosteric moiety determine the fraction of ligand bound in one or the other pose, according to 
the model published by Bock et al. (2014). Based on this model, the dualsteric ligand distributes 
over the receptor population with the fraction of the respective subpopulation determined by the 
affinity ratio between the active signaling-competent (dualsteric) and the inactive (allosteric) pose.  
Thus, this result supports the idea that isox-6-naph increases in allosteric binding pose in the low 
osmolarity buffer. Yet, OOM-6-naph displayed only a slight increase in allosteric binding affinity in 
Tris vs. Tris NaCl buffer (Fig. 3.32). This effect was comparable to the increase in orthosteric 
affinity of the orthosteric building block OOM (Fig. 3.19). Even if these data indicate that OOM-6-
naph does not display increased allosteric binding in Tris buffer, the dominant binding pose under 
these conditions is the allosteric one, as indicated by the inverse agonism seen at the 
spontaneously active M2AChR (Fig. 3.30).  
 
One might argue that protean agonism of isox-6-naph and OOM-6-naph resides in the rather low 
efficacy of the two ligands and is not necessarily due to dynamic ligand binding. However, 
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dualsteric ligands such as isox-6-phth and OOM-6-phth did not display any protean agonism 
although the efficacy of these compounds did not differ significantly from the efficacy of the two 
protean agonists at the quiescent M2AChR (Fig. 4.4). In sum, these data indicate that dynamic 
ligand binding (Bock et al., 2014) is the underlying molecular mechanism for protean agonism of 
isox-6-naph and OOM-6-naph at M2AChR.  
Of note, we also observed an increase in allosteric binding for iper-6-naph, iper-8-naph, ALB3 and 
ALB4 to the M2 receptor in Tris compared to Tris NaCl (Fig. 3.32) although these four compounds 
clearly did not display any protean agonism. For iper-6-naph and iper-8-naph this might be 
explained by the higher intrinsic efficacy for receptor activation of the orthosteric moiety iper in 
comparison to isox and OOM. In consequence, the beneficial effect of the spontaneously active M2 
receptor on the orthosteric superagonist iperoxo (increase in binding affinity 10-fold in Tris vs. Tris 
NaCl) surpassed the increase in allosteric binding (increase in allosteric binding affinity 3.5-fold and 
7-fold for iper-6-naph and iper-8-naph, respectively) and this precluded protean agonism. 
Regarding ALB3 and ALB4, even though the increase in allosteric binding in Tris was 12-times and 
8-times, respectively, their allosteric affinity was presumably too low to adopt a prevailing purely 
allosteric pose. Indeed, ALB3 and ALB4 are composed of an allosteric moiety that presents an 
additional ring in its chemical structure that impairs the allosteric affinity (Fig. 3.24), as already 
reported in previous work (De Min, Master Thesis, 2012).   
 
4.3.1 Equilibrium binding experiments further strengthen the proposed mechanism for 
dualsteric protean agonism 
 
Equilibrium binding studies performed in Tris and Tris NaCl buffer further confirmed that the 
prevailing binding pose of the protean agonists isox-6-naph and OOM-6-naph is the pure allosteric 
pose. Indeed, these two ligands showed either positive or neutral cooperativity with [3H]NMS, that 
is indicative of allosteric binding (Fig. 3.35). Regarding isox-6-naph, the compound increases 
radioligand binding both in Tris and Tris NaCl buffer; this result suggests that the allosteric binding 
pose is preferred in both buffers. On the other hand, OOM-6-naph was neutrally cooperative with 
the radioligand in Tris buffer and slightly negative cooperative in Tris NaCl buffer. Thus, the data 
steer to an increase in dualsteric binding of the OOM-derived hybrid in the high osmolarity buffer, 
i.e. under conditions similar to those applied in the functional assays where partial agonism is 
reported for this compound.  
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One might claim that a model estimating the fraction of compound bound in one or the other pose 
was recently published for dualsteric hybrids binding the M2 receptor (Bock et al., 2014) and could 
be the final corroboration of our hypothesized mechanism. Unfortunately, the model could not be 
applied here, since it does not account for the inverse agonism induced by the ligands in Tris 
buffer. Thus, a more extended mathematical model would be required to fit the data presented in 
this thesis.   
 
4.4 A functional allosteric site is critical for stimulating protean agonism at M2 
 
The functional and binding data collected for the dualsteric hybrids at the wild type M2 receptor 
pointed to dynamic ligand binding as the underlying mechanism for protean agonism. Thus, the 
adoption of a purely allosteric binding pose is of fundamental importance for this hypothesized 
mechanism. The next question was whether a mutation in this binding site would abolish protean 
agonism of isox-6-naph and OOM-6-naph. We chose to mutate the residue W422 to alanine, since 
this tryptophan is known to be part of a series of amino acids lining the core region of the 
allosteric site and to be critical for allosteric ligand binding (Prilla et al., 2006; Haga et al., 2012). 
Since the spontaneous activity reported at the wild type M2 was present also at the mutant 
receptor when assayed in Tris buffer, and abolished in the presence of 200 mM NaCl (Fig. 3.36), 
we were convinced that the conditions necessary for identifying protean agonists were present 
also at the mutant receptor. Furthermore, the tested orthosteric agonists were still able to induce 
a positive response (Fig. 3.37), a result that is indicative of a functional orthosteric site. Thus, a 
group of dualsteric ligands was investigated in Tris and Tris NaCl buffers for Gi-signaling 
stimulation at the M2422W→A and it was found that the protean activity of isox-6-naph and OOM-6-
naph was absent at this allosteric loss-of-affinity mutant. Moreover, all compounds had an 
increased Emax in Tris and/or Tris NaCl buffer in comparison to the Emax reported at the wild type 
M2 receptor (Fig. 4.5).  
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Figure 4.5: Comparison between the Emax of dualsteric ligands at the wild type M2 and the mutant 
M2422W→A in Tris and Tris NaCl. n.d.: not determined. The bar diagrams show means ± SEM of 3-6 
independent experiments performed in triplicate. *,**,***: (p<0.05, 0.01, 0.001), significantly different from 
the value reported at the wild type receptor according to a two-tailed t-test. 
 
This is consistent with previous findings by Bock et al. (2012), who found an increased efficacy of 
the dualsteric ligands tested in the study when investigated at the mutant M2422W→A in comparison 
to the wild type receptor. This result might be explained considering that the allosteric loss-of-
affinity mutant is expected to have an impaired allosteric site. As a consequence, the 
(antagonistic) allosteric moieties embedded in the dualsteric ligands may be unable to properly 
bind to this site, resulting in both decreased antagonistic effects (and thus an increased Emax of the 
dualsteric compounds) and a reduction in pure allosteric binding pose of the tested ligands.  
Taken together, a fully functional allosteric binding site is of major importance for inducing 
dualsteric protean agonism, as allosteric binding of the antagonistic moieties of the ligands is 
necessary for guarantying a prevailing purely allosteric pose of the dualsteric protean agonists. 
 
4.5 The level of spontaneous activity influences the apparent efficacy of both 
orthosteric and dualsteric agonists 
 
One of the main findings of this thesis is that the spontaneous activity of the M2 receptor can be 
titrated by buffer osmolarity and that this enables the recognition of protean agonists at this 
receptor subtype, and virtually at other GPCRs. Interestingly, a receptor system with a sustained 
level of constitutive activity and another with low levels of spontaneous activity also allowed us to 
determine whether there were differences in apparent efficacy not only of the two identified 
protean agonists, but also of the full and partial agonists tested.  
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In the low osmolarity Tris buffer (Tris), both basal and also agonist-induced [35S]GTPγS binding 
were increased in CHO-M2 membranes in comparison with a buffer system with high 
concentrations of sodium (Tris NaCl) or potassium ions (Tris KCl) (Fig. 3.13). This is in line with 
previous findings (Tian et al., 1994) for the adrenergic α2-AR and reflects a stronger stimulus-
response-coupling and ternary complex formation of agonist, receptor and G protein of the 
spontaneously active M2 receptor compared to quiescent M2. 
Accordingly, almost all dualsteric compounds which did not display protean agonism showed 
increased Emax values and all orthosteric agonists gained binding affinity and potency in Tris 
compared to Tris NaCl buffer, indicating that agonists prefer binding to an active rather than an 
inactive receptor, as already confirmed in previous work (De Lean et al., 1980). The classical 
muscarinic partial agonist pilocarpine was an exception to this behavior as the compound changed 
neither in potency nor in efficacy depending on the buffer composition. Correspondingly, a 
previous report (Tota and Schimerlik, 1990) described that pilocarpine does not distinguish 
between active and inactive receptors.  
Taken together, the two M2 receptor systems, i.e. a constitutively active and an inactive system, 
conveyed a means to identify the different apparent efficacies of muscarinic ligands upon binding 
at a spontaneous or quiescent receptor. The data indicated that (i) orthosteric full agonists prefer 
to bind to spontaneously active receptors, as demonstrated by the increase in potency/affinity of 
these ligands and that (ii) for dualsteric ligands their binding preference is structure-dependent. 
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5 SUMMARY 
Protean agonists are of great pharmacological interest as their apparent efficacy may change in 
magnitude and direction depending on the constitutive activity of a receptor. Yet, this intriguing 
phenomenon has been poorly described and understood, due to the lack of stable experimental 
systems and design strategies. In this thesis, the main aim was to investigate whether a dualsteric 
design principle, i.e. molecular probes carrying two pharmacophores to simultaneously adopt 
orthosteric and allosteric topography within a G protein-coupled receptor, may represent a novel 
approach to generate protean agonism at the M2 receptor. First, we overcame the methodological 
limitations: we established two experimental systems, which have either a high level of 
spontaneous activity (Tris buffer) or a low amount of constitutive activity (Tris NaCl buffer), and 
we demonstrated that a high buffer osmolarity rather than a high concentration of sodium ions is 
responsible for receptor inactivation. Then, we identified two new dualsteric protean agonists at 
the M2 muscarinic acetylcholine receptors, namely isox-6-naph and OOM-6-naph and we 
pinpointed three molecular requirements within dualsteric compounds that elicit protean agonism 
at this receptor subtype: (i) an orthosteric part endowed with an acetylcholine-like efficacy, (ii) a 
bulky allosteric part to impair the flexibility of the extracellular loop area, and (iii) a flexible linker 
chain of 6 carbon atoms.   
Using radioligand binding and functional assays we posit that dynamic ligand binding may be the 
mechanism underlying protean agonism of dualsteric ligands. Therefore, given that protean 
agonism was thought to reside in the intrinsic efficacy of a ligand, these results introduce an 
unprecedented molecular mechanism to elicit protean agonism.  
Finally, assays performed with an allosteric loss-of-affinity mutant confirmed that a functional 
allosteric site is critical for eliciting protean agonism at the M2 receptor. Indeed, a single mutation 
in this binding site converted the behaviour of isox-6-naph and OOM-6-naph from protean to 
partial agonism. 
In conclusion, the findings of this thesis provide new mechanistic insights into the still enigmatic 
phenomenon of protean agonism and form a rationale for the design of such compounds for a G 
protein-coupled receptor. 
Thus, in addition to the great potential of biased GPCR signaling, improved understanding of 
protean agonism may provide another level towards a targeted exploitation of the GPCR signaling 
machinery, which could be relevant to the knowledge-based design of innovative drug candidates.  
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6 ABBREVIATION LIST 
 
[35S]GTPγS Guanosine 5'-O-(gamma-[35S]thio)triphosphate) 
[3H]NMS [3H]N-methylscopolamine 
°C Degrees Celsius 
5-HT1BR Serotonin receptor 1B 
7TMs Seven transmembrane helices 
A Alanine 
ACh Acetylcholine 
ANOVA Analysis of variance 
ATCM Allosteric ternary complex model 
Atr Atropine 
ATSM Allosteric two-state model 
B2R Bradykinin receptor 2 
BSA Bovine serum albumine 
cAMP Cyclic adenosine monophosphate 
CB2R Cannabinoid receptor 2  
CHO Chinese hamster ovary 
CHO-hM2 CHO stably expressing the human muscarinic acetylcholine M2 receptor 
CNS Central nervous system 
DTT DL-dithiothreitol 
FCS Fetal calf serum 
G proteins Guanine nucleotide-binding proteins 
GDP Guanosine diphosphate 
GIRKs G protein-coupled inwardly-rectifying potassium channels 
GPCR G protein-coupled receptors 
GRKs G protein-coupled receptor kinases  
GTP Guanosine triphosphate 
H3R Histamine receptor 3 
Ham’s F-12 Ham’s nutrient mixture F-12 
HEPES 4-(2-Hydroxyethyl)-1-piperazineethane sulfonic acid 
HSA Human Serum Albumin 
IKACh Acetylcholine-activated potassium channel 
iper Iperoxo 
M2AChR Muscarinic acetylcholine receptor 2  
mAChRs Muscarinic acetylcholine receptors 
min Minutes 
MWC model Monod, Wyman and Changeux model 
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nAChRs Nicotinic acetylcholine receptors 
NMDG N-methyl-D-glucamine 
NMS N-methylscopolamine 
NMS N-methylscopolamine 
OOM Oxo-oxotremorine M  
PBS Phosphate buffered saline 
PKA Protein kinase A 
PKC Protein kinase C 
PLCβ Phospholipase C beta  
PNS Peripheral nervous system 
RGS Regulators of G-protein signalling 
SEM Standard error of mean 
Thr Threonine 
Tris Tris(hydroxymethyl)aminomethane 
Trp Tryptophan 
Tyr Tyrosine 
W Tryptophan 
wt Wild type 
α2AAR Alpha-2A adrenergic receptor 
β2AR Beta-2 adrenergic receptor 
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